Screener / SEC EDGAR /CIK 0000818686 /10-K filed Feb 3, 2026, compared with Feb 5, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Teva Pharmaceutical Industries Ltd TEVA

Compare with peers Embed
Earnings releases

Latest results release: Nov 3, 2026

8-K item 2.02, exhibit 99

What TEVA's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of May 8, 2024, TEVA reported −$0.12 per share under GAAP and $0.48 on its own adjusted basis.

ReleaseGAAP EPSAdjusted EPSGap
May 8, 2024 -0.12 0.48 –
The company's words, latest release
GAAP loss per share of $0.12 release
Non-GAAP diluted EPS of $0.48 release

What the company says its adjusted numbers leave out:

Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the third quarter of 2026 were adjusted to exclude the following items: release Nov 3, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 3, 2026 · EX-99.1

Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative

Open on SEC

EXHIBIT 99.1 Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION OF BXCL-501

2026 Business Outlook - Innovative brand revenues outlook increased, non-GAAP operating income outlook increased for underlying operational performance, offset by increased IPR&D:

*IPR&D impact is presented due to uncertainty of the future occurrence and timing of these transactions

TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2026.

Richard Francis, Teva's President and CEO, said: “Our strong third-quarter performance is another clear demonstration of Pivot to Growth in action and how far Teva has come. The FDA approval of WELTRUZA has further advanced our innovative portfolio, our recently announced biosimilars agreement with Samsung Bioepis has strengthened our generics powerhouse and our return to investment grade reflects the transformation of our financial position. Together, these achievements represent how we are delivering sustained innovative growth and translating that growth into greater profitability, with our three key innovative brands collectively growing 33% in local currency to approximately $1.1 billion year-over-year. This performance, together with continued margin expansion and cash flow generation, gives us the confidence to raise our 2026 revenue outlook for all three brands.”

Mr. Francis added: “At the same time, we are continuously building the next phase of sustainable growth at Teva. The U.S. launch of WELTRUZA expands our schizophrenia franchise, while progress across ecopipam, anti-IL-15 and our broader late-stage pipeline supports our ambition to deliver at least five potential innovative launches over five years. Our return to investment grade and debt refinancing reflect our strengthened financial position.”

In the third quarter of 2026 and into October 2026, Teva continued to execute on the four pillars of its Pivot to Growth strategy:

Teva’s key innovative brands, AUSTEDO, AJOVY and UZEDY, collectively generated approximately $1.1 billion in revenues and grew 33% year-over-year in local currency. Strong performance across all three brands supports increased 2026 revenue outlooks of these products and continues to shift Teva’s portfolio toward innovative medicines. The FDA approval and U.S. launch of WELTRUZA further expand Teva’s long-acting injectable schizophrenia portfolio and builds on the commercial momentum established by UZEDY.

Teva continued to advance a differentiated late-stage pipeline across neuroscience and immunology. The FDA accepted ecopipam's (EBS-101) NDA for review, positive Phase 2a results were reported for anti-IL-15 (TEV-‘408) in Celiac disease, and the anti-IL-15 program is planned to advance into Phase 2b development in vitiligo later this year. Together with the acquisition of BXCL-501 (dexmetomidine sublingual film) from BioXcel Therapeutics, these milestones expand Teva’s capabilities in areas of significant unmet need and support its ambition to deliver a sustained cadence of potential launches.

Teva continues to strengthen its global generics business through an increased focus on complex generics and biosimilars. While global generics revenues declined primarily due to lower revenues of lenalidomide capsules (a generic version of Revlimid) in the U.S., revenues from biosimilars continued to expand. Teva currently expects more than $0.8 billion in biosimilars revenues in 2026, reaching its original 2027 revenue objective one year early, with further portfolio expansion supported by new collaborations, including the recently announced agreement with Samsung Bioepis.

Teva continued to transform and modernize its business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support the Company’s objective of achieving a 30% non-GAAP operating income margin and approximately $700 million of net savings, by 2027 including ~two-thirds expected to be realized in 2026. At the same time, Teva continued to maintain disciplined capital allocation and strengthen its financial profile. During Q3 2026, Moody’s and S&P upgraded Teva to investment grade, following Fitch’s earlier upgrade; and Teva refinanced ~$4.9 billion of debt. All these reflect Teva's goal to achieve two times debt leverage by the end of 2027.

Revenues in the third quarter of 2026 were $4,395 million, a decrease of 2% in both U.S. dollars and local currency terms compared to the third quarter of 2025. This decrease was mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid) in our U.S. segment, partially offset by higher revenues from our key innovative products, primarily AUSTEDO, AJOVY and UZEDY.

Exchange ratemovements in the third quarter of 2026, net of hedging effects, positively impacted revenues by $5 million, compared to the third quarter of 2025.

Gross profit in the third quarter of 2026 was $2,440 million, an increase of 6% compared to $2,304 million in the third quarter of 2025. Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025. Non-GAAP gross profit was $2,580 million in the third quarter of 2026, an increase of 4% compared to $2,475 million in the third quarter of 2025. Non-GAAP gross profit margin was 58.7% in the third quarter of 2026, compared to 55.3% in the third quarter of 2025. The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products, primarily higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid).

Research and Development (R&D) expenses, net in the third quarter of 2026, were $297 million, an increase of 16% compared to $256 million in the third quarter of 2025. This increase was mainly due to higher expenses in our immunology and neuroscience projects, as well as in our biosimilars pipeline. Our R&D expenses, net in the third quarters of 2026 and 2025, were also impacted by reimbursements and cost sharing from our strategic partnerships and collaborations entered into in recent years.

Selling and Marketing (S&M) expenses in the third quarter of 2026, were $709 million, an increase of 8% compared to the third quarter of 2025. This increase was mainly due to promotional activities related to our key innovative products, primarily AUSTEDO, and other innovative product launch preparation activities in our U.S. segment.

General and Administrative (G&A) expensesin the third quarter of 2026 were $298 million, a decrease of 6% compared to the third quarter of 2025.

Other Income in the third quarter of 2026 was $68 million, compared to other loss of $7 million in the third quarter of 2025, mainly related to a capital gain from the sale of a property in Europe.

Operating Incomewas $714 million in the third quarter of 2026, compared to an operating income of $882 million in the third quarter of 2025. Operating Income as a percentage of revenues was 16.2% in the third quarter of 2026, compared to 19.7% in the third quarter of 2025. This decrease was mainly due to higher tangible asset impairments and higher legal settlements and loss contingencies, partially offset by an increase in gross profit. Non-GAAP operating income in the third quarter of 2026 was $1,393 million representing a non-GAAP operating margin of 31.7% compared to $1,294 million representing 28.9%, respectively, in the third quarter of 2025. This increase in non-GAAP operating margin in the third quarter of 2026 was mainly due to higher gross profit margin as described above.

Exchange rate movements in the third quarter of 2026, net of hedging effects, had a negative impact of $2 million on our operating income and non-GAAP operating income compared to the third quarter of 2025.

Financial expenses, net in the third quarter of 2026, were $414 million, mainly comprised of a loss of $224 million on extinguishment of debt and net interest expenses of $174 million. In the third quarter of 2025, financial expenses, net were $237 million, mainly comprised of net interest expenses of $209 million.

In the third quarter of 2026, we recognized a tax expense of $66 million on pre- tax income of $300 million. In the third quarter of 2025, we recognized a tax expense of $214 million on pre-tax income of $646 million.

Ourtax rate in the third quarter of 2026 was 22.1%, compared to 33.1% in the third quarter of 2025. Non-GAAP tax rate in the third quarter of 2026 was 16.5%, compared to 14.7% in the third quarter of 2025. Our tax rate and non-GAAP tax rate in the third quarter of 2026 were mainly affected by the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate and other infrequent or non-recurring items. Our tax rate and non-GAAP tax rate in the third quarter of 2025 were mainly affected by changes in deferred tax balances due to statutory tax rate changes and interest and inflation adjustments related to the agreement with the Israeli Tax Authorities.

Considering the above, we expect our annual non-GAAP tax rate for 2026 to be between 20%-23%, higher than our non-GAAP tax rate for 2025, which was 15.8%.

Net incomeattributable to Teva and diluted earnings per sharein the third quarter of 2026 were $233 million and $0.20, respectively, compared to net income attributable to Teva and diluted earnings per share of $433 million and $0.37, respectively, in the third quarter of 2025. This decrease was mainly due to lower operating income, as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the third quarter of 2026 were $1,013 million and $0.86, respectively, compared to $910 million and $0.78, respectively, in the third quarter of 2025.

Adjusted EBITDA was $1,496 million in the third quarter of 2026, an increase of 7%, compared to $1,394 million in the third quarter of 2025.

As of September 30, 2026 and 2025, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,195 million shares and 1,184 million shares, respectively.

Non-GAAP information: non-GAAP adjustments in the third quarter of 2026 were $780 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the third quarter of 2026 were adjusted to exclude the following items:

We believe that excluding such items facilitates investors’ understanding of our business including underlying trends, thereby improving the comparability of our business performance results between reporting periods.

For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under “Non-GAAP Financial Measures.” Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.

Cash flow generated from operating activities during the third quarter of 2026 was $241 million compared to $369 million in the third quarter of 2025. The lower cash flow generated from operating activities in the third quarter of 2026 resulted mainly from the timing of sales and collections, partially offset by lower legal settlement payments.

During the third quarter of 2026, we generated free cash flow of $495 million, which we define as comprising: $241 million in cash flow generated from operating activities, $327 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $47 million of proceeds from the sale of businesses and long-lived assets, partially offset by $120 million in cash used for capital investments. During the third quarter of 2025, we generated free cash flow of $515 million, which we define as comprising $369 million in cash flow generated from operating activities, $274 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $8 million of proceeds from the sale of businesses and long-lived assets, partially offset by $136 million in cash used for capital investments. The decrease in the third quarter of 2026 resulted mainly from lower cash flow generated from operating activities, as discussed above, partially offset by higher proceeds from the sale of businesses and long-lived assets.

As of September 30, 2026, our debt was $16,718 million, compared to $16,807 million as of December 31, 2025. This decrease was mainly due to $256 million of exchange rate fluctuations. In addition, during the third quarter of 2026, we consummated an early redemption of $4,678 million in aggregate principal amount of senior notes and concurrently, issued $4,837 million of new senior notes, net of discount and issuance costs. The portion of total debt classified as short-term as of September 30, 2026 was 24% compared to 11% as of December 31, 2025. Our financial leverage, which is the ratio between our debt and the sum of our debt and equity, was 68% as of September 30, 2026 and December 31, 2025. Our average debt maturity was approximately 6.3 years as of September 30, 2026, compared to 5.6 years as of December 31, 2025.

In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. This shift allows the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation. As a result, from that date, Anda is reported as part of the Company’s Other Activities. Prior period amounts were recast to reflect this change.

The following table presents revenues, expenses and profit for our United States segment for the three months ended September 30, 2026 and 2025:

_______________________ * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5% as applicable.

Revenues from our United States segment in the third quarter of 2026 were $1,870 million, a decrease of 11% compared to the third quarter of 2025, mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid), partially offset by higher revenues from our key innovative products, primarily AUSTEDO, AJOVY, and UZEDY.

The following table presents revenues for our United States segment by major products and activities for the three months ended September 30, 2026 and 2025:

Generic products(including biosimilar products) revenues in our United States segment in the third quarter of 2026 were $718 million, a decrease of 39% compared to the third quarter of 2025. This decrease was mainly driven by lower revenues from lenalidomide capsules (a generic version of Revlimid) due to increased generic competition in the U.S., partially offset by higher revenues from our portfolio of biosimilar products and from recently launched generic products.

Among the most significant generic products we sold in the United States in the third quarter of 2026 were epinephrine injectable solution (a generic equivalent of EpiPen and EpiPen Jr), TRUXIMA (a biosimilar to Rituxan), and SIMLANDI (a biosimilar to Humira). In the third quarter of 2026, our total prescriptions were approximately 227 million (based on trailing twelve months), representing 5.8% of total U.S. generic prescriptions, compared to approximately 261 million (based on trailing twelve months), representing 6.7% of total U.S. generic prescriptions in the third quarter of 2025, all according to IQVIA data.

On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab- adet) as a biosimilar to Xgeva (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy.

AJOVYrevenues in our United States segment in the third quarter of 2026 were $138 million, an increase of 88% compared to the third quarter of 2025, mainly due to a reduction in sales allowance as well as growth in volume. In the third quarter of 2026, AJOVY’s exit market share in the United States in terms of total number of prescriptions was 32.8% out of the subcutaneous injectable anti-CGRP class, compared to 32.2% in the third quarter of 2025.

AUSTEDO revenues (which include AUSTEDO XR) in our United States segment in the third quarter of 2026 were $727 million, an increase of 21%, compared to the third quarter of 2025. This increase was mainly due to growth in volume and a favorable business mix including improved net-price realization.

AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023. The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024. AUSTEDO XR is a once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease, which is additional to the twice-daily AUSTEDO.

UZEDY(risperidone) extended-release injectable suspension revenues in our United States segment in the third quarter of 2026 were $85 million, an increase of 96% compared to the third quarter of 2025, mainly due to growth in volume.

On October 9, 2026, we announced that the FDA approved WELTRUZA (olanzapine) for extended-release injectable suspension, a new once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. WELTRUZA is expected to become available in the U.S. in the coming weeks, in three different strengths (318 mg, 425 mg, 531 mg). In May 2026, the European Medicines Agency accepted Teva’s Marketing Authorization Application for olanzapine LAI (TEV-’749). WELTRUZA is protected in the U.S. by four Orange Book listed patents expiring between 2033 and 2044, and in Europe by five granted patents expiring between 2031 and 2044.

BENDEKA and TREANDA combined revenues in our United States segment in the third quarter of 2026 were $30 million, a decrease of 15% compared to the third quarter of 2025, mainly due to competition from alternative therapies, as well as from branded and generic bendamustine products.

COPAXONE revenues in our United States segment in the third quarter of 2026 were $58 million, a decrease of 8% compared to the third quarter of 2025.

Gross profitfrom our United States segment in the third quarter of 2026 was $1,403 million, a decrease of 3%, compared to the third quarter of 2025.

Gross profit margin for our United States segment in the third quarter of 2026 increased to 75.0%, compared to 69.1% in the third quarter of 2025. This increase was mainly due to a favorable mix of products, primarily higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from lenalidomide capsules (a generic version of Revlimid).

Profit from our United States segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our United States segment in the third quarter of 2026 was $791 million, a decrease of 15% compared to $927 million in the third quarter of 2025. This decrease was mainly due to higher S&M expenses and lower gross profit, as discussed above.

Our Europe segment includes the European Union, the United Kingdom and certain other European countries.

The following table presents revenues, expenses and profit for our Europe segment for the three months ended September 30, 2026 and 2025:

_______________________ * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5%, as applicable.

Revenues from our Europe segment in the third quarter of 2026 were $1,319 million, an increase of 7% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This increase was mainly due to higher revenues from generic products, higher proceeds from the sale of certain product rights, and higher revenues from AJOVY.

In the third quarter of 2026, revenues were negatively impacted by exchange rate fluctuations of $7 million, net of hedging effects, compared to the third quarter of 2025. Revenues in the third quarter of 2026 included $17 million from a positive hedging impact, compared to $6 million in the third quarter of 2025, which are included in “Other” in the table below.

The following table presents revenues for our Europe segment by major products and activities for the three months ended September 30, 2026 and 2025:

_______________________ * Other revenues in the third quarters of 2026 and 2025 include the sale of certain product rights.

Generic productsrevenues (including OTC and biosimilar products) in our Europe segment in the third quarter of 2026 were $1,033 million, an increase of 5% compared to the third quarter of 2025. In local currency terms, revenues increased by 7%, mainly due to higher sales of generic and OTC products, including from recently launched products.

AJOVYrevenues in our Europe segment in the third quarter of 2026 were $84 million, an increase of 28% compared to the third quarter of 2025. In local currency terms revenues increased by 29% mainly due to higher volumes.

COPAXONE revenues in our Europe segment in the third quarter of 2026 were $38 million, a decrease of 12% compared to the third quarter of 2025. In local currency terms revenues decreased by 11%, mainly due to price reductions and lower volumes resulting from the availability of alternative therapies.

Respiratory products revenues in our Europe segment in the third quarter of 2026 were $54 million, an increase of 3% compared to the third quarter of 2025. In local currency terms, revenues increased by 4%, mainly due to higher volumes as a result of increased supply.

Gross profitfrom our Europe segment in the third quarter of 2026 was $757 million, an increase of 14% compared to the third quarter of 2025. Gross profit margin for our Europe segment in the third quarter of 2026 increased to 57.4%, compared to 53.9% in the third quarter of 2025. This increase was mainly due to higher proceeds from the sale of certain product rights and a positive impact from hedging activities.

Profit from our Europe segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our Europe segment in the third quarter of 2026 was $420 million, an increase of 39%, compared to the third quarter of 2025. This increase was mainly due to higher gross profit, as discussed above.

Our International Markets segment includes all countries in which we operate other than the United States and the countries included in our Europe segment. The International Markets segment covers a substantial portion of the global pharmaceutical industry, including more than 35 countries. The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, and branded generics-oriented markets, such as Russia and certain Latin America markets.

As of the date of this Quarterly Report on Form 10-Q, sustained conflict between Russia and Ukraine and disruption in the region is ongoing. Russia and Ukraine markets are included in our International Markets segment results and we have no manufacturing or R&D facilities in these markets. In September 2026, a warehouse that we share with other pharmaceutical companies in Ukraine was damaged, and, as of the date of this Quarterly Report on Form 10-Q, operations at this warehouse resumed. The impact of this conflict on our International Markets segment in the third quarter of 2026 was immaterial.

The following table presents revenues, expenses and profit for our International Markets segment for the three months ended September 30, 2026 and 2025:

_______________________ * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5%, as applicable.

Revenues from our International Markets segment in the third quarter of 2026 were $592 million, an increase of 6% compared to the third quarter of 2025. In local currency terms, revenues increased by 4% compared to the third quarter of 2025, mainly due to higher revenues from our key innovative products AJOVY and AUSTEDO.

In the third quarter of 2026, revenues were positively impacted by exchange rate fluctuations of $13 million, including hedging effects, compared to the third quarter of 2025. Revenues in the third quarter of 2026 included $7 million from a positive hedging impact, compared to $2 million in the third quarter of 2025, which are included in “Other” in the table below.

The following table presents revenues for our International Markets segment by major products and activities for the three months ended September 30, 2026 and 2025:

_______________________*Other revenues in the third quarters of 2026 and 2025 include the sale of certain product rights.

Generic products revenues (including OTC and biosimilar products) in our International Markets segment in the third quarter of 2026 were $407 million, a decrease of 3% compared to the third quarter of 2025. In local currency terms, revenues decreased by 4%, mainly due to lower revenues from generic and OTC products in certain markets including Ukraine.

AJOVYrevenues in our International Markets segment in the third quarter of 2026 were $48 million, an increase of 61% in both U.S. dollars and local currency terms compared to the third quarter of 2025. This increase was mainly due to growth in multiple markets. In April 2026, we announced a strategic partnership for the marketing and distribution of AJOVY in China with Nuerogen (Zhuhai) Pharmaceutical Company Ltd.

AUSTEDOrevenues in our International Markets segment in the third quarter of 2026 were $24 million, an increase of 42% compared to the third quarter of 2025. In local currency terms, revenue increased by 34% compared to the third quarter of 2025, mainly due to growth in China.

COPAXONE revenues in our International Markets segment in the third quarter of 2026 were $8 million, an increase of 8% compared to the third quarter of 2025.

Gross profit from our International Markets segment in the third quarter of 2026 was $316 million, an increase of 14% compared to the third quarter of 2025.

Gross profit margin for our International Markets segment in the third quarter of 2026 increased to 53.3%, compared to 49.8% in the third quarter of 2025. This increase was mainly due to a favorable mix of products, primarily attributed to higher revenues from AJOVY and AUSTEDO, partially offset by lower revenues from generic products, as discussed above.

Profit from our International Markets segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profitfrom our International Markets segment in the third quarter of 2026 was $125 million, an increase of 32%, compared to the third quarter of 2025. This increase was mainly due to higher gross profit, as discussed above.

We have other sources of revenues, primarily our distribution business in the United States to third parties through Anda, the sale of APIs to third parties, an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis, and certain contract manufacturing services. Our Other Activities are not included in our United States, Europe or International Markets segments described above.

In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda

In 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale. The intention to divest is in alignment with our Pivot to Growth strategy, and Teva is conducting a sales process for this matter. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be completed at all.

Our revenues from Other Activities in the third quarter of 2026 were $613 million, an increase of 3% in both U.S. dollars and local currency terms, compared to the third quarter of 2025.

Anda revenues from third-party products in the third quarter of 2026 were $401 million, an increase of 2%, compared to the third quarter of 2025, mainly due to higher volumes. Anda, our distribution business in the United States, operates independently and distributes generic and innovative medicines and OTC pharmaceutical products from various manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda competes in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States.

API sales to third parties in the third quarter of 2026 were $115 million, a decrease of 8% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This decrease was mainly due to lower demand resulting from market dynamics and temporary supply challenges.

Revenues from additional other activities, mainly from Medis and certain contract manufacturing services, were $98 million in the third quarter of 2026, an increase of 21% in U.S. dollars, or 23% in local currency terms compared to the third quarter of 2025, mainly due to higher demand.

$ billions, except Prior Updated Key diluted EPS or as Guidance Guidance Assumptions noted Assume growth in Revenues $16.5 - $16.85 $16.7 - $17.0 innovative products AUSTEDO ($m) 2,450 - 2,600 2,550 - 2,650 AJOVY ($m) 850 - 870 930 - 960 UZEDY ($m) 270 - 290 290 - 310 Increase of $0.05B before updating Operating Income* 3.8 - 4.0 3.8 - 3.9 guidance for $0.1B impact of acquired IPR&D charge Adjusted EBITDA* 4.23 - 4.53 4.23 - 4.43 Finance Expenses* ~$0.8 ~$0.8 Tax Rate* 20% - 23% 20% - 23% Increase of $0.08 at midpoint before updating guidance Diluted EPS* ($) 1.91 - 2.11 1.92 - 2.11 for $0.07 impact of acquired IPR&D charge Free Cash Flow* 2.0 - 2.4 2.1 - 2.4 CAPEX 0.5 0.5 Volatile swings in Foreign Exchange FX can negatively impact revenue and income

Financial guidance only assumes business development transactions closed as of November 3, 2026.

Certain items above are non-GAAP financial measures. For more information, see “Non-GAAP Financial Measures” below. Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.

Teva will host a conference call and live webcast along with a slide presentation on Tuesday, November 3, 2026 at 8:00 a.m. ET to discuss its third quarter 2026 financial results and overall business environment.

In order to participate, please register in advance to obtain a local or toll‐free phone number and your personal pin.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit .

Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts.

This press release contains certain financial information that differs from what is reported under accounting principles generally accepted in the United States (“GAAP”). These non-GAAP financial measures, including, but not limited to, non-GAAP operating income, non-GAAP operating margin, non-GAAP gross profit, non-GAAP gross profit margin, Adjusted EBITDA, free cash flow, non-GAAP tax rate, non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS, are presented in order to facilitate investors' understanding of our business. We utilize certain non-GAAP financial measures to evaluate performance in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational performance and, to compare our results against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are prepared on a non-GAAP basis; and senior management’s annual compensation is derived, in part, using these non-GAAP measures. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP measures. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing the most comparable forward-looking GAAP measures for non-GAAP metrics included in our financial outlook or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” "will", “expect,” “aim”, “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe”, “outlook”, “transition” and other words and terms of similar meaning and expression in connection with any discussion of future operating financial performance or development. Important factors that could cause or contribute to such differences include risks relating to:

other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.“ Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Consolid… Statemen… of Income (U.S. dollars in millions, except share and per share data) (Unaudit… Three Nine months months ended ended September September 30, 30, 2026 2025 2026 2025 Net $ 4,395 $ 4,480 $ 12,519 $ 12,547 revenues Cost of 1,955 2,176 5,954 6,264 sales Gross 2,440 2,304 6,565 6,282 profit Research and 297 256 1,489 746 developm… expenses Selling and 709 656 2,122 1,933 marketing expenses General and 298 317 919 920 administ… expenses Intangib… assets 24 64 54 227 impairme… Other asset impairme… 264 62 438 272 restruct… and other items Legal settleme… 202 60 504 312 and loss continge… Other loss -68 7 -96 15 (income) Operating income 714 882 1,135 1,857 (loss) Financial expenses, 414 237 854 714 net Income (loss) before 300 646 282 1,143 income taxes Income taxes 66 214 254 210 (benefit) Share in (profits) losses of * -2 * -4 associat… companie… net Net income 234 434 27 937 (loss) Net income (loss) attribut… to 1 1 1 7 redeemab… and non-rede… non-cont… interest Net income (loss) 233 433 26 930 attribut… to Teva Earnings (loss) per share Basic $ 0.20 $ 0.38 $ 0.02 $ 0.81 attribut… to Teva: Diluted $ 0.20 $ 0.37 $ 0.02 $ 0.80 Weighted average number of Basic 1,166 1,147 1,162 1,144 shares (in millions… Diluted 1,183 1,164 1,180 1,160 Non-GAAP net income attribut… to Teva 1,013 910 1,655 2,281 for diluted earnings per share:** Non-GAAP earnings per share Diluted $ 0.86 $ 0.78 $ 1.40 $ 1.97 attribut… to Teva:** Non-GAAP average number of Diluted 1,183 1,164 1,180 1,160 shares (in millions… Amounts may not add up due to rounding. * Represen… an amount less than $0.5 million. ** See reconcil… attached.

CONSOLIDATED BALANCE SHEETS (U.S. dollars in millions, except for share data) (Unaudited) ASSETS September 30, December 31, Current assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash equivalents $ 4,085 $ 3,556 Accounts receivables, net of allowance for credit losses of $71 million and $81 million 3,837 3,709 as of September 30, 2026 and December 31, 2025, respectively. Inventories 3,173 3,179 Prepaid expenses 1,014 1,122 Other current assets 658 539 Assets held for sale 1,836 1,842 Total current assets 14,602 13,946 Deferred income taxes 2,057 2,191 Other non-current assets 269 405 Property, plant and 3,747 4,080 equipment, net Operating lease right-of-use 321 345 assets, net Identifiable intangible 3,303 3,781 assets, net Goodwill 15,742 16,000 Total assets $ 40,042 $ 40,748 LIABILITIES AND EQUITY Current liabilities: Short-term debt $ 4,038 $ 1,820 Sales reserves and allowances 3,955 4,143 Accounts payables 2,551 2,531 Employee-related obligations 588 739 Accrued expenses 2,962 2,687 Other current liabilities 1,036 1,182 Liabilities held for sale 296 354 Total current liabilities 15,425 13,456 Long-term liabilities: Deferred income taxes 263 296 Other taxes and long-term 3,422 3,808 liabilities Senior notes and loans 12,680 14,986 Operating lease liabilities 266 288 Total long-term liabilities 16,632 19,379 Equity: Teva shareholders’ equity: 7,979 7,910 Non-controlling interests 5 4 Total equity 7,984 7,914 Total liabilities and equity $ 40,042 $ 40,748 Amounts may not add up due to rounding.

TEVA PHARMACEUTI… INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in millions) (Unaudited) Three months Nine months Operating ended ended activities: September 30, 2026 2025 September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 234 434 $ 27 937 (loss) Adjustments to reconcile net income (loss) to net cash provided by operations: Depreciation and 245 249 725 742 amortization Impairment of long-lived 228 79 350 255 assets and assets held for sale Acquired in-process 23 17 785 52 research and development* Net change in operating -682 -578 -1,523 -1,647 assets and liabilities Deferred income taxes – net and 53 107 56 -76 uncertain tax positions Stock-based 38 34 121 106 compensation Loss on extinguishm… 224 - 224 - of debt Other items -53 27 -65 122 Net loss (gain) from sale of business -69 - -89 - and long-lived assets Net cash provided by (used in) 241 369 612 491 operating activities Investing activities: Beneficial interest collected in exchange for 327 274 992 932 securitized accounts receivables Purchases of property, plant and equipment -120 -136 -393 -359 and intangible assets Proceeds from sale of businesses 47 8 93 34 and long-lived assets, net Purchases of in-process -46 -12 -747 -41 research and development* Other investing 2 1 3 6 activities Net cash provided by (used in) 210 135 -52 572 investing activities Financing activities: Repayment of senior notes and loans and -4,883 -444 -4,906 -4,112 other long-term liabilities Proceeds from senior notes, net 4,845 -7 4,845 2,298 of issuance costs Purchase of shares from redeemable and - - - -38 non-redeema… non-control… interests Dividends paid to redeemable and - - - -340 non-redeema… non-control… interests Other financing 43 -2 78 1 activities Net cash provided by (used in) 6 -453 18 -2,191 financing activities Effect of exchange rate changes -27 -9 -49 31 on cash and cash equivalents Net change in cash and 430 42 529 -1,097 cash equivalents Balance of cash and cash equivalents 3,655 2,161 $ 3,556 3,300 at beginning of period Balance of cash and cash equivalents $ 4,085 2,203 $ 4,085 2,203 at end of period Non-cash financing and investing activities: Beneficial interest obtained in exchange $ 253 296 $ 859 937 for securitized accounts receivables Receivable for sale of 90 - 90 - long-lived assets * In the first nine months of 2026, mainly related to the acquisition of Emalex and its primary asset ecopipam (EBS-101). Amounts may not add up due to rounding. The accompanying notes are an integral part of the financial statements.

($ in millions except per share amounts) Net income (Loss) attributable to Teva Increase (decrease) for excluded items: Amortization of purchased intangible assets Legal settlements and loss contingenci… Impairment of long-lived assets(2) Restructuri… costs(3) Equity compensation Three Contingent months Nine months considerati… ended ended Financial September September expenses(4) 30, 30, Other 2026 2025 2026 2025 Reconcilia… non-GAAP 233 433 26 930 of net items(5) 139 144 415 436 income Correspondi… 201 60 503 309 (loss) tax effects 228 79 350 255 attributab… and unusual 58 29 121 196 to Teva tax items(6) 38 34 121 106 to Non-GAAP Non-GAAP net 2 16 25 46 net income income 235 7 256 58 (loss) attributable 14 51 55 170 attributab… to Teva (134) 58 (216) (225) to Teva Non-GAAP tax 1,013 910 1,655 2,281 (Unaudited) rate(7) 16.5 % 14.7 % 22.1 % 16.0 % ────────────────────────────────────────────────────────────────────────────── GAAP diluted earnings (loss) per $ 0.20 0.37 $ 0.02 0.80 share attributable to Teva EPS 0.66 0.41 1.38 1.16 difference(… Non-GAAP diluted EPS $ 0.86 0.78 $ 1.40 1.97 attributable to Teva(8) Non-GAAP average number of 1,183 1,164 1,180 1,160 shares (in millions)(8) For the three months ended September 30, 2026, adjustments for legal settlements and loss contingenci… mainly consisted of (a) an update to the estimated provision recorded in connection with one of the Company’s ongoing antitrust litigations in the amount of $133 million, and (b) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $35 million. For the nine months ended September 30, 2026, adjustments for legal settlements and loss contingenci… mainly consisted of (a) an estimated provision recorded in connection with one of the Company’s ongoing antitrust litigations in the amount of $250 million, and (b) (1) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $132 million. For the three and nine months ended September 30, 2025, adjustments of legal settlements and loss contingenci… mainly consisted of (a) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $42 million and $139 million, respectivel… and (b) an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the U.S. in the generic drug antitrust litigation in the amount of $55 million. The expense for the three and nine months ended September 30, 2026, mainly consisted of (a) impairment charges in connection with several manufacturi… facilities in Europe in the amount of $140 million and $210 million, respectivel… and (b) impairment charges in connection with the held for sale measurement of the API business (including its R&D, manufacturi… (2) and commercial activities), which includes an impact related to the expected gain from reclassific… of currency translation adjustments in the amount of $49 million and $66 million, respectivel… For the nine months ended September 30, 2025, the adjustment for impairment of long-lived assets was mainly related to intangible assets in the U.S. and Europe. In the nine months ended September 30, 2026 and 2025, Teva recorded restructuri… expenses of $121 million and $196 million, respectivel… primarily related to optimization (3) activities in connection with Teva’s Transformat… programs related to Teva’s global organization and operations mainly through headcount reduction. In the three and nine months ended September 30, 2026, Teva recorded (4) $224 million of finance expenses related to a loss on extinguishm… of debt. Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an (5) understandi… of trends in our financial results, primarily related to material litigation fees, rationaliza… of our plants, accelerated depreciation and other unusual events. Adjustments for correspondi… tax effects and unusual tax items exclusively consisted of the tax impact directly (6) attributable to the pre-tax items that are excluded from non-GAAP net income included in the other adjustments to this table. Non-GAAP tax rate is tax expenses (benefit) excluding the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP adjustments presented above. Our non-GAAP tax rate in the nine months ended September 30, 2026 was mainly affected by an unfavorable tax impact (7) of a non-deducti… acquired IPR&D charge related to the acquisition of Emalex and its primary asset ecopipam (EBS-101), the generation of profits in various jurisdictio… in which tax rates are different than the Israeli tax rate, and other infrequent or non-recurri… items, such as internal legal entities reorganizat… EPS difference and diluted non-GAAP EPS are calculated by dividing our (8) non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares.

Reconciliation of gross profit to Non-GAAP gross profit (Unaudited) Three months Nine months ended ended September 30, September 30, ($ in millions) 2026 2025 2026 2025 Gross profit $ 2,440 2,304 $ 6,565 6,282 Gross profit 55.5% 51.4% 52.4% 50.1% margin Increase (decrease) for excluded items: (1) Amortization of purchased 129 134 387 406 intangible assets Equity 6 6 18 17 compensation Other non-GAAP 5 32 11 101 items Non-GAAP gross $ 2,580 2,475 $ 6,981 6,807 profit Non-GAAP gross profit margin 58.7% 55.3% 55.8% 54.3% (2) (1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table. (2) Non-GAAP gross profit margin is non-GAAP gross profit as a percentage of revenue.

Reconciliation of operating income (loss) to Non-GAAP operating income (loss) (Unaudited) Three months Nine months ended ended September 30, September 30, ($ in millions) 2026 2025 2026 2025 Operating $ 714 882 $ 1,135 1,857 income (loss) Operating 16.2 % 19.7 % 9.1 % 14.8 % margin Increase (decrease) for excluded items: (1) Amortization of purchased 139 144 415 436 intangible assets Legal settlements and 201 60 503 309 loss contingencies Impairment of long-lived 228 79 350 255 assets Restructuring 58 29 121 196 costs Equity 38 34 121 106 compensation Contingent 2 16 25 46 consideration Loss (gain) on sale of -1 6 -5 19 business Other non-GAAP 15 45 60 149 items Non-GAAP operating $ 1,393 1,294 $ 2,724 3,373 income (loss) Non-GAAP operating 31.7 % 28.9 % 21.8 % 26.9 % margin(2) (1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table. (2) Non-GAAP operating margin is Non-GAAP operating income as a percentage of revenues.

Reconcilia… of net income (loss) to adjusted EBITDA (Unaudited) Three months Nine months ended ended September 30, September 30, ($ in 2026 2025 2026 2025 millions) Net income $ 234 434 $ 27 937 (loss) Increase (decrease) for excluded items:(1) Financial 414 237 854 714 expenses Income taxes 66 214 254 210 Share in profits (losses) of § -2 § -4 associated companies –net Depreciation 106 105 311 306 Amortization 139 144 415 436 EBITDA 959 1,131 1,861 2,599 Legal settlements 201 60 503 309 and loss contingenci… Impairment of long 228 79 350 255 lived assets Restructuri… 58 29 121 196 costs Equity 38 34 121 106 compensation Contingent 2 16 25 46 considerati… Loss (Gain) on sale of -1 6 -5 19 Business Other non-GAAP 12 40 50 137 items Adjusted $ 1,496 1,394 $ 3,025 3,668 EBITDA (1) For further explanatio… refer to the footnotes under the "Reconcili… of net income (loss) attributab… to Teva to Non-GAAP net income (loss) attributab… to Teva" table. § Represents an amount of less than $0.5 million.

Reconciliation of our segment profit Three months ended to consolidated income (loss) before September 30, income taxes (U.S.$ in millions) 2026 2025 ────────────────────────────────────────────────────────────────────────────── United States profit $ 791 $ 927 Europe profit 420 303 International Markets profit 125 95 Total reportable segment profit 1,336 1,325 Profit (loss) of other activities 57 -31 Amounts not allocated to segments: Amortization 139 144 Other asset impairments, restructuring 264 62 and other items Intangible asset impairments 24 64 Legal settlements and loss 201 60 contingencies Other unallocated amounts 51 82 Consolidated operating income (loss) 714 882 Financial expenses - net 414 237 Consolidated income (loss) before income $ 300 $ 646 taxes

Nine months ended Reconciliation of our September 30, segment profit September 30, to consolidated income 2026 (loss) before income taxes (U.S.$ in millions) 2025 ────────────────────────────────────────────────────────────────────────────── United States profit $ 1,222 $ 2,143 Europe profit 1,188 996 International Markets 289 266 profit Total reportable segment 2,699 3,405 profit Profit (loss) of other 25 -32 activities Amounts not allocated to segments: Amortization 415 436 Other asset impairments, restructuring 438 272 and other items Intangible asset 54 227 impairments Legal settlements and loss 503 309 contingencies Other unallocated amounts 179 272 Consolidated operating 1,135 1,857 income (loss) Financial expenses - net 854 714 Consolidated income (loss) before income $ 282 $ 1,143 taxes

Segment revenues by major products and activities Three months ended (Unaudited) September 30, Percentage United States 2026 Change segment (U.S.$ in millions) 2025 2026-2025 ────────────────────────────────────────────────────────────────────────────── Generic products (including $ 718 $ 1,175 (39)% biosimilars) AJOVY 138 73 88 % AUSTEDO 727 601 21 % BENDEKA and TREANDA 30 35 (15)% COPAXONE 58 62 (8)% UZEDY 85 43 96 % Other 114 101 13 % Total 1,870 2,090 (11)% Three months ended Percentage September 30, Change 2026 2025 2026-2025 -U.S.$ in millions Europe segment Generic products (including OTC and $ 1,033 $ 982 5 % biosimilars) AJOVY 84 66 28 % COPAXONE 38 44 (12)% Respiratory 54 52 3 % products Other* 111 91 21 % Total 1,319 1,235 7 % *Other revenues in the third quarter of 2026 and 2025 include the sale of certain product rights Three months ended Percentage September 30, Change 2026 2025 2026-2025 -U.S.$ in millions International Markets segment Generic products (including OTC and $ 407 $ 421 (3)% biosimilars) AJOVY 48 30 61 % AUSTEDO 24 17 42 % COPAXONE 8 8 8 % Other* 105 82 28 % Total 592 557 6 % *Other revenues in the third quarter of 2026 and 2025 include the sale of certain product rights

Segment revenues by major products Nine months ended and activities September 30, (Unaudited) 2026 Percentage United States (U.S.$ in Change segment millions) 2025 2025-2026 ────────────────────────────────────────────────────────────────────────────── Generic $ 1,990 $ 2,984 (33)% products AJOVY 341 190 80 % AUSTEDO 1,963 1,492 32 % BENDEKA / 85 111 (24)% TREANDA COPAXONE 182 179 2 % UZEDY 225 136 65 % Other 321 321 § Total 5,106 5,413 (6)% § Represents an amount less than 0.5%. Nine months ended September 30, Percentage Change 2026 2025 2025-2026 -U.S.$ in millions Europe segment Generic $ 3,146 $ 3,011 4 % products AJOVY 238 195 22 % COPAXONE 127 135 (6)% Respiratory 171 162 6 % products Other* 241 223 8 % Total 3,922 3,726 5 % *Other revenues in the first nine months of 2026 and 2025 include the sale of certain product rights. Nine months ended September 30, Percentage Change 2026 2025 2025-2026 -U.S.$ in millions International Markets segment Generic $ 1,212 $ 1,298 (7)% products AJOVY 130 78 68 % AUSTEDO 63 34 82 % COPAXONE 22 25 (13)% Other* 239 199 20 % Total 1,666 1,634 2 % *Other revenues in the first nine months of 2026 and 2025 include the sale of certain product rights.

Free cash flow reconciliation (Unaudited) Three months ended September 30, 2026 2025 -U.S. $ in millions Net cash provided by (used in) operating 241 369 activities Beneficial interest collected in exchange for 327 274 securitized account receivables Capital investment -120 -136 Proceeds from sale of businesses and 47 8 long-lived assets, net Free cash flow $ 495 $ 515

Free cash flow reconciliation (Unaudited) Nine months ended September 30, 2026 2025 -U.S. $ in millions Net cash provided by (used in) operating 612 491 activities Beneficial interest collected in exchange for securitized 992 932 trade receivables Capital investment -393 -359 Proceeds from sale of businesses and 93 34 long-lived assets, net Free cash flow $ 1,305 $ 1,098

Net debt reconciliation unaudited September 30, 2026 Short-term debt 4,038 Senior notes and loans 12,680 Total debt 16,718 Net of cash and cash equivalents 4,085 Net debt $ 12,633

Full text with the tables
                                                                    EXHIBIT 99.1
   Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative    
     Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers      
                       Substantial Gross Margin Expansion                       
COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC
ADDITION OF BXCL-501
                                                                                
  Q3 2026 revenues of $4.4 billion                                              
                                                                                
                                                                                
  AUSTEDO                                                                       
                                                                                
                                                                                
  AJOVY                                                                         
                                                                                
                                                                                
  UZEDY                                                                         
                                                                                
Q3 2026 Highlights:

2026 Business Outlook - Innovative brand revenues outlook increased, non-GAAP
operating income outlook increased for underlying operational performance,
offset by increased IPR&D:

*IPR&D impact is presented due to uncertainty of the future occurrence and
timing of these transactions

TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical
Industries Ltd. (NYSE and TASE: TEVA) today reported results
for the quarter ended September 30, 2026.

Richard Francis, Teva's President and CEO, said: “Our strong third-quarter
performance is another clear demonstration
of Pivot to Growth in action and how far Teva has come. The FDA approval of
WELTRUZA has further advanced our innovative portfolio, our
recently announced biosimilars agreement with Samsung Bioepis has strengthened
our generics powerhouse and our return to investment grade
reflects the transformation of our financial position. Together, these
achievements represent how we are delivering sustained innovative
growth and translating that growth into greater profitability, with our three
key innovative brands collectively growing 33% in local
currency to approximately $1.1 billion year-over-year. This performance,
together with continued margin expansion and cash flow generation,
gives us the confidence to raise our 2026 revenue outlook for all three brands.”

Mr. Francis added: “At the same time, we are continuously building the next
phase of sustainable growth at Teva. The U.S. launch
of WELTRUZA expands our schizophrenia franchise, while progress across ecopipam,
anti-IL-15 and our broader late-stage pipeline supports
our ambition to deliver at least five potential innovative launches over five
years. Our return to investment grade and debt refinancing
reflect our strengthened financial position.”

Pivot to Growth Strategy

In the third quarter of 2026 and into October 2026, Teva continued to execute on
the four pillars of its Pivot to Growth strategy:

Delivering on our growth engines

Teva’s key innovative brands, AUSTEDO, AJOVY and UZEDY, collectively generated
approximately $1.1 billion in revenues and grew
33% year-over-year in local currency. Strong performance across all three brands
supports increased 2026 revenue outlooks of these products
and continues to shift Teva’s portfolio toward innovative medicines. The FDA
approval and U.S. launch of WELTRUZA further expand
Teva’s long-acting injectable schizophrenia portfolio and builds on the
commercial momentum established by UZEDY.

Stepping up innovation

Teva continued to advance a differentiated late-stage pipeline across
neuroscience and immunology. The FDA accepted ecopipam's (EBS-101)
NDA for review, positive Phase 2a results were reported for anti-IL-15
(TEV-‘408) in Celiac disease, and the anti-IL-15 program
is planned to advance into Phase 2b development in vitiligo later this year.
Together with the acquisition of BXCL-501 (dexmetomidine
sublingual film) from BioXcel Therapeutics, these milestones expand Teva’s
capabilities in areas of significant unmet need and support
its ambition to deliver a sustained cadence of potential launches.

Sustaining our generics powerhouse

Teva continues to strengthen its global generics business through an increased
focus on complex generics and biosimilars. While global
generics revenues declined primarily due to lower revenues of lenalidomide
capsules (a generic version of Revlimid) in
the U.S., revenues from biosimilars continued to expand. Teva currently expects
more than $0.8 billion in biosimilars revenues in 2026,
reaching its original 2027 revenue objective one year early, with further
portfolio expansion supported by new collaborations, including
the recently announced agreement with Samsung Bioepis.

Focusing our business

Teva continued to transform and modernize its business through the Teva
Transformation programs, which combined with innovative product
growth potential, is expected to support the Company’s objective of achieving a
30% non-GAAP operating income margin and approximately
$700 million of net savings, by 2027 including ~two-thirds expected to be
realized in 2026. At the same time, Teva continued to maintain
disciplined capital allocation and strengthen its financial profile. During Q3
2026, Moody’s and S&P upgraded Teva to investment
grade, following Fitch’s earlier upgrade; and Teva refinanced ~$4.9 billion of
debt. All these reflect Teva's goal to achieve two
times debt leverage by the end of 2027.

Third Quarter 2026 Consolidated Results

Revenues in the third quarter of 2026 were $4,395 million, a decrease of 2% in
both U.S. dollars and local currency
terms compared to the third quarter of 2025. This decrease was mainly due to
lower revenues from generic products, primarily lenalidomide
capsules (a generic version of Revlimid) in our U.S. segment, partially offset
by higher revenues from our key innovative
products, primarily AUSTEDO, AJOVY and UZEDY.

Exchange ratemovements in the third quarter of 2026, net of hedging effects,
positively impacted revenues by $5 million,
compared to the third quarter of 2025.

Gross profit in the third quarter of 2026 was $2,440 million, an increase of 6%
compared to $2,304 million in the
third quarter of 2025. Gross profit margin was 55.5% in the third quarter of
2026, compared to 51.4% in the third quarter
of 2025. Non-GAAP gross profit was $2,580 million in the third quarter of 2026,
an increase of 4% compared to $2,475
million in the third quarter of 2025. Non-GAAP gross profit margin was 58.7% in
the third quarter of 2026, compared to
55.3% in the third quarter of 2025. The increase in both gross profit margin and
non-GAAP gross profit margin was mainly due to a favorable
mix of products, primarily higher revenues from our key innovative products,
largely AUSTEDO, partially offset by lower revenues from
generic products, primarily lenalidomide capsules (a generic version of
Revlimid).

Research and Development (R&D) expenses, net in the third quarter of 2026, were
$297 million,
an increase of 16% compared to $256 million in the third quarter of 2025. This
increase was mainly due to higher expenses in our immunology
and neuroscience projects, as well as in our biosimilars pipeline. Our R&D
expenses, net in the third quarters of 2026 and 2025, were
also impacted by reimbursements and cost sharing from our strategic partnerships
and collaborations entered into in recent years.

Selling and Marketing (S&M) expenses in the third quarter of 2026, were $709
million, an increase of 8% compared
to the third quarter of 2025. This increase was mainly due to promotional
activities related to our key innovative products, primarily
AUSTEDO, and other innovative product launch preparation activities in our U.S.
segment.

General and Administrative (G&A) expensesin the third quarter of 2026 were $298
million, a decrease of 6% compared
to the third quarter of 2025.

Other Income in the third quarter of 2026 was $68 million, compared to other
loss of $7 million in the third quarter
of 2025, mainly related to a capital gain from the sale of a property in Europe.

Operating Incomewas $714 million in the third quarter of 2026, compared to an
operating income of $882 million in
the third quarter of 2025. Operating Income as a percentage of revenues was
16.2% in the third quarter of 2026, compared to 19.7% in the
third quarter of 2025. This decrease was mainly due to higher tangible asset
impairments and higher legal settlements and loss contingencies,
partially offset by an increase in gross profit. Non-GAAP operating income in
the third quarter of 2026 was $1,393 million
representing a non-GAAP operating margin of 31.7% compared to $1,294 million
representing 28.9%, respectively, in the third quarter of
2025. This increase in non-GAAP operating margin in the third quarter of 2026
was mainly due to higher gross profit margin as described
above.

Exchange rate movements in the third quarter of 2026, net of hedging effects,
had a negative impact of $2 million
on our operating income and non-GAAP operating income compared to the third
quarter of 2025.

Financial expenses, net in the third quarter of 2026, were $414 million, mainly
comprised of a loss of $224 million
on extinguishment of debt and net interest expenses of $174 million. In the
third quarter of 2025, financial expenses, net were $237 million,
mainly comprised of net interest expenses of $209 million.

In the third quarter of 2026, we recognized a tax expense of $66 million on pre-
tax income of $300 million. In the third quarter of
2025, we recognized a tax expense of $214 million on pre-tax income of $646
million.

Ourtax rate in the third quarter of 2026 was 22.1%, compared to 33.1% in the
third quarter of 2025. Non-GAAP tax rate in the third quarter of 2026 was 16.5%,
compared to 14.7% in the third quarter of 2025. Our tax rate and non-GAAP tax
rate in the third quarter of 2026 were mainly affected by the generation of
profits in various jurisdictions in which tax rates are different
than the Israeli tax rate and other infrequent or non-recurring items. Our tax
rate and non-GAAP tax rate in the third quarter of 2025
were mainly affected by changes in deferred tax balances due to statutory tax
rate changes and interest and inflation adjustments related
to the agreement with the Israeli Tax Authorities.

Considering the above, we expect our annual non-GAAP tax rate for 2026 to be
between 20%-23%, higher than our non-GAAP tax rate for
2025, which was 15.8%.

Net incomeattributable to Teva and diluted earnings per sharein the third
quarter
of 2026 were $233 million and $0.20, respectively, compared to net income
attributable to Teva and diluted earnings per share of $433
million and $0.37, respectively, in the third quarter of 2025. This decrease was
mainly due to lower operating income, as discussed above.
Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share
in the third quarter
of 2026 were $1,013 million and $0.86, respectively, compared to $910 million
and $0.78, respectively, in the third quarter of 2025.

Adjusted EBITDA was $1,496 million in the third quarter of 2026, an increase of
7%, compared to $1,394 million in
the third quarter of 2025.

As of September 30, 2026 and 2025, the fully diluted share count for purposes of
calculating our market capitalization
was approximately 1,195 million shares and 1,184 million shares, respectively.

Non-GAAP information: non-GAAP adjustments in the third quarter of 2026 were
$780 million. Non-GAAP net income attributable
to Teva and non-GAAP diluted EPS for the third quarter of 2026 were adjusted to
exclude the following items:

We believe that excluding such items facilitates investors’ understanding of our
business including underlying trends, thereby
improving the comparability of our business performance results between
reporting periods.

For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures
and for additional information, see the tables below
and the information included under “Non-GAAP Financial Measures.” Investors
should consider non-GAAP financial measures in
addition to, and not as replacement for, or superior to, measures of financial
performance prepared in accordance with GAAP.

Cash flow generated from operating activities during the third quarter of 2026
was $241 million compared to $369 million
in the third quarter of 2025. The lower cash flow generated from operating
activities in the third quarter of 2026 resulted mainly from
the timing of sales and collections, partially offset by lower legal settlement
payments.

During the third quarter of 2026, we generated free cash flow of $495 million,
which we define as comprising: $241
million in cash flow generated from operating activities, $327 million in
beneficial interest collected in exchange for securitized accounts
receivables (under our EU securitization program) and $47 million of proceeds
from the sale of businesses and long-lived assets, partially
offset by $120 million in cash used for capital investments. During the third
quarter of 2025, we generated free cash flow of $515 million,
which we define as comprising $369 million in cash flow generated from operating
activities, $274 million in beneficial interest collected
in exchange for securitized accounts receivables (under our EU securitization
program) and $8 million of proceeds from the sale of businesses
and long-lived assets, partially offset by $136 million in cash used for capital
investments. The decrease in the third quarter of 2026
resulted mainly from lower cash flow generated from operating activities, as
discussed above, partially offset by higher proceeds from
the sale of businesses and long-lived assets.

As of September 30, 2026, our debt was $16,718 million, compared to $16,807
million as of December 31, 2025. This
decrease was mainly due to $256 million of exchange rate fluctuations. In
addition, during the third quarter of 2026, we consummated
an early redemption of $4,678 million in aggregate principal amount of senior
notes and concurrently, issued $4,837 million
of new senior notes, net of discount and issuance costs. The portion of total
debt classified as short-term as of September 30, 2026 was
24% compared to 11% as of December 31, 2025. Our financial leverage, which is
the ratio between our debt and the sum of our debt and equity,
was 68% as of September 30, 2026 and December 31, 2025. Our average debt
maturity was approximately 6.3 years as of September 30, 2026,
compared to 5.6 years as of December 31, 2025.

Segment Results for the third quarter of 2026

United States Segment

In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda
is no longer reported under our United States segment.
This shift allows the United States segment to continue to manage its entire
product portfolio in the region, while strengthening focus
on its biopharmaceutical business, growth engines and innovation. As a result,
from that date, Anda is reported as part of the Company’s
Other Activities. Prior period amounts were recast to reflect this change.

The following table presents revenues, expenses and profit for our United States
segment for the three months ended September 30, 2026
and 2025:
                                                                                
                   Three months                                                 
                   ended                                                        
                   September 30,                                                
                   2026                                                         
                   (U.S. $ in                                                   
                   millions / % of                                              
                   Segment Revenues)                     2025                   
 ────────────────────────────────────────────────────────────────────────────── 
  Revenues         $                  1,870    100 %     $     2,090    100 %   
  Cost of sales                         467    25.0 %            645    30.9 %  
  Gross profit                        1,403    75.0 %          1,446    69.1 %  
  R&D expenses                          196    10.5 %            161    7.7 %   
  S&M expenses                          306    16.4 %            248    11.8 %  
  G&A expenses                          109    5.9 %             113    5.4 %   
  Other                                   §    §                  -3    §       
  Segment profit*  $                    791    42.3 %    $       927    44.3 %  
                                                                                
_______________________
* Segment profit does not include amortization and certain other items.
§ Represents
an amount less than $0.5 million or 0.5% as applicable.

Revenues from our United States segment in the third quarter of 2026 were $1,870
million, a decrease of 11% compared
to the third quarter of 2025, mainly due to lower revenues from generic
products, primarily lenalidomide capsules (a generic version of
Revlimid), partially offset by higher revenues from our key innovative products,
primarily AUSTEDO, AJOVY, and UZEDY.

Revenues by Major Products and Activities

The following table presents revenues for our United States segment by major
products and activities for the three months ended September
30, 2026 and 2025:
                                                                                
                        Three months ended                                      
                        September                                               
                        30,                                                     
                        2026                                        Percentage  
                        (U.S.$ in                                   Change      
                        millions)                    2025           2026-2025   
 ────────────────────────────────────────────────────────────────────────────── 
  Generic products                                                              
  (including            $                     718    $     1,175    (39)%       
  biosimilars)                                                                  
  AJOVY                                       138             73    88%         
  AUSTEDO                                     727            601    21%         
  BENDEKA and                                  30             35    (15)%       
  TREANDA                                                                       
  COPAXONE                                     58             62    (8)%        
  UZEDY                                        85             43    96%         
  Other                                       114            101    13%         
  Total                 $                   1,870    $     2,090    (11)%       
                                                                                
Generic products(including biosimilar products) revenues in our United States
segment in the third quarter
of 2026 were $718 million, a decrease of 39% compared to the third quarter of
2025. This decrease was mainly driven by lower revenues
from lenalidomide capsules (a generic version of Revlimid) due to increased
generic competition in the U.S., partially
offset by higher revenues from our portfolio of biosimilar products and from
recently launched generic products.

Among the most significant generic products we sold in the United States in the
third quarter of 2026 were epinephrine injectable solution
(a generic equivalent of EpiPen and EpiPen Jr), TRUXIMA (a biosimilar to
Rituxan),
and SIMLANDI (a biosimilar to Humira). In the third quarter of 2026, our total
prescriptions were approximately
227 million (based on trailing twelve months), representing 5.8% of total U.S.
generic prescriptions, compared to approximately 261 million
(based on trailing twelve months), representing 6.7% of total U.S. generic
prescriptions in the third quarter of 2025, all according to
IQVIA data.

On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab-
adet) as a biosimilar to Xgeva
(denosumab). DEGEVMA is indicated for the prevention of bone complications in
adults with advanced cancer that has spread to the bone,
for the treatment of adults and skeletally mature adolescents with giant cell
tumor of bone, and for the treatment of hypercalcemia of
malignancy.

AJOVYrevenues in our United States segment in the third quarter of 2026 were
$138 million, an increase of 88% compared
to the third quarter of 2025, mainly due to a reduction in sales allowance as
well as growth in volume. In the third quarter of 2026,
AJOVY’s exit market share in the United States in terms of total number of
prescriptions was 32.8% out of the subcutaneous injectable
anti-CGRP class, compared to 32.2% in the third quarter of 2025.

AUSTEDO revenues (which include AUSTEDO XR) in our United States segment in the
third quarter of
2026 were $727 million, an increase of 21%, compared to the third quarter of
2025. This increase was mainly due to growth in volume and
a favorable business mix including improved net-price realization.

AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA
on February 17, 2023 in three doses of 6, 12 and 24
mg, and became commercially available in the U.S. in May 2023. The FDA approved
AUSTEDO XR as a one pill, once-daily treatment option
in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024. AUSTEDO
XR is a once-daily formulation indicated in adults for
tardive dyskinesia and chorea associated with Huntington’s disease, which is
additional to the twice-daily AUSTEDO.

UZEDY(risperidone) extended-release injectable suspension revenues in our United
States segment in the third quarter
of 2026 were $85 million, an increase of 96% compared to the third quarter of
2025, mainly due to growth in volume.

On October 9, 2026, we announced that the FDA approved WELTRUZA (olanzapine) for
extended-release injectable suspension,
a new once-monthly, subcutaneous long-acting injectable (LAI) for the treatment
of schizophrenia in adults. WELTRUZA is expected to become
available in the U.S. in the coming weeks, in three different strengths (318 mg,
425 mg, 531 mg). In May 2026, the European Medicines
Agency accepted Teva’s Marketing Authorization Application for olanzapine LAI
(TEV-’749). WELTRUZA is protected in the U.S.
by four Orange Book listed patents expiring between 2033 and 2044, and in Europe
by five granted patents expiring between 2031 and 2044.

BENDEKA and TREANDA combined revenues in our United States segment
in the third quarter of 2026 were $30 million, a decrease of 15% compared to the
third quarter of 2025, mainly due to competition from
alternative therapies, as well as from branded and generic bendamustine
products.

COPAXONE revenues in our United States segment in the third quarter of 2026 were
$58 million, a decrease
of 8% compared to the third quarter of 2025.

United States Gross Profit

Gross profitfrom our United States segment in the third quarter of 2026 was
$1,403 million, a decrease of 3%, compared
to the third quarter of 2025.

Gross profit margin for our United States segment in the third quarter of 2026
increased to 75.0%, compared to 69.1%
in the third quarter of 2025. This increase was mainly due to a favorable mix of
products, primarily higher revenues from our key innovative
products, largely AUSTEDO, partially offset by lower revenues from lenalidomide
capsules (a generic version of Revlimid).

United States Profit

Profit from our United States segment consists of revenues less cost of sales,
R&D expenses, S&M expenses, G&A expenses
and other expenses (income) related to this segment. Segment profit does not
include amortization and certain other items.

Profit from our United States segment in the third quarter of 2026 was $791
million, a decrease of 15% compared to
$927 million in the third quarter of 2025. This decrease was mainly due to
higher S&M expenses and lower gross profit, as discussed
above.

Europe Segment

Our Europe segment includes the European Union, the United Kingdom and certain
other European countries.

The following table presents revenues, expenses and profit for our Europe
segment for the three months ended September 30, 2026 and
2025:
                                                                                
                     Three months                                               
                     ended September                                            
                     30,                                                        
                     2026                                                       
                     (U.S. $ in                                                 
                     millions / % of                                            
                     Segment                                                    
                     Revenues)                           2025                   
 ────────────────────────────────────────────────────────────────────────────── 
  Revenues           $                1,319    100 %     $     1,235    100 %   
  Cost of sales                         562    42.6 %            570    46.1 %  
  Gross profit                          757    57.4 %            665    53.9 %  
  R&D expenses                           62    4.7 %              62    5.0 %   
  S&M expenses                          211    16.0 %            225    18.2 %  
  G&A expenses                           64    4.8 %              75    6.1 %   
  Other                                   §    §                   §    §       
  Segment profit*    $                  420    31.8 %    $       303    24.5 %  
                                                                                
_______________________
* Segment profit does not include amortization and certain other items.
§ Represents
an amount less than $0.5 million or 0.5%, as applicable.

Revenues from our Europe segment in the third quarter of 2026 were $1,319
million, an increase of 7% in both U.S.
dollars and local currency terms, compared to the third quarter of 2025. This
increase was mainly due to higher revenues from generic
products, higher proceeds from the sale of certain product rights, and higher
revenues from AJOVY.

In the third quarter of 2026, revenues were negatively impacted by exchange rate
fluctuations of $7 million, net of hedging effects,
compared to the third quarter of 2025. Revenues in the third quarter of 2026
included $17 million from a positive hedging impact, compared
to $6 million in the third quarter of 2025, which are included in “Other” in the
table below.

Revenues by Major Products and Activities

The following table presents revenues for our Europe segment by major products
and activities for the three months ended September
30, 2026 and 2025:
                                                                                
                        Three months ended                                      
                        September                                               
                        30,                                                     
                        2026                                        Percentage  
                        (U.S.$ in                                   Change      
                        millions)                    2025           2026-2025   
 ────────────────────────────────────────────────────────────────────────────── 
  Generic products                                                              
  (including OTC and    $                   1,033    $       982    5%          
  biosimilars)                                                                  
  AJOVY                                        84             66    28%         
  COPAXONE                                     38             44    (12)%       
  Respiratory                                  54             52    3%          
  products                                                                      
  Other*                                      111             91    21%         
  Total                 $                   1,319    $     1,235    7%          
                                                                                
_______________________
* Other revenues in the third quarters of 2026 and 2025 include the sale of
certain product rights.

Generic productsrevenues (including OTC and biosimilar products) in our Europe
segment in the third quarter of 2026
were $1,033 million, an increase of 5% compared to the third quarter of 2025. In
local currency terms, revenues increased by 7%, mainly
due to higher sales of generic and OTC products, including from recently
launched products.

AJOVYrevenues in our Europe segment in the third quarter of 2026 were $84
million, an increase of 28% compared to
the third quarter of 2025. In local currency terms revenues increased by 29%
mainly due to higher volumes.

COPAXONE revenues in our Europe segment in the third quarter of 2026 were $38
million, a decrease of 12% compared
to the third quarter of 2025. In local currency terms revenues decreased by 11%,
mainly due to price reductions and lower volumes resulting
from the availability of alternative therapies.

Respiratory products revenues in our Europe segment in the third quarter of 2026
were $54 million, an increase of
3% compared to the third quarter of 2025. In local currency terms, revenues
increased by 4%, mainly due to higher volumes as a result
of increased supply.

Europe Gross Profit

Gross profitfrom our Europe segment in the third quarter of 2026 was $757
million, an increase of 14% compared to
the third quarter of 2025. Gross profit margin for our Europe segment in the
third quarter of 2026 increased to 57.4%,
compared to 53.9% in the third quarter of 2025. This increase was mainly due to
higher proceeds from the sale of certain product rights
and a positive impact from hedging activities.

Europe Profit

Profit from our Europe segment consists of revenues less cost of sales, R&D
expenses, S&M expenses, G&A expenses and other
expenses (income) related to this segment. Segment profit does not include
amortization and certain other items.

Profit from our Europe segment in the third quarter of 2026 was $420 million, an
increase of 39%, compared to the
third quarter of 2025. This increase was mainly due to higher gross profit, as
discussed above.

International Markets Segment

Our International Markets segment includes all countries in which we operate
other than the United States and the countries included
in our Europe segment. The International Markets segment covers a substantial
portion of the global pharmaceutical industry, including
more than 35 countries. The countries in our International Markets segment
include highly regulated, mainly generic markets, such as Canada
and Israel, and branded generics-oriented markets, such as Russia and certain
Latin America markets.

As of the date of this Quarterly Report on Form 10-Q, sustained conflict between
Russia and Ukraine and disruption in the region is
ongoing. Russia and Ukraine markets are included in our International Markets
segment results and we have no manufacturing or R&D
facilities in these markets. In September 2026, a warehouse that we share with
other pharmaceutical companies in Ukraine was damaged,
and, as of the date of this Quarterly Report on Form 10-Q, operations at this
warehouse resumed. The impact of this conflict on our International
Markets segment in the third quarter of 2026 was immaterial.

The following table presents revenues, expenses and profit for our International
Markets segment for the three months ended September
30, 2026 and 2025:
                                                                                
                   Three months ended                                           
                   September 30,                                                
                   2026                                                         
                   (U.S. $ in millions /                                        
                   % of Segment                                                 
                   Revenues)                               2025                 
 ────────────────────────────────────────────────────────────────────────────── 
  Revenues         $                      592    100 %     $     557    100 %   
  Cost of sales                           276    46.7 %          280    50.2 %  
  Gross profit                            316    53.3 %          278    49.8 %  
  R&D expenses                             31    5.3 %            26    4.6 %   
  S&M expenses                            125    21.2 %          122    21.9 %  
  G&A expenses                             34    5.7 %            36    6.4 %   
  Other                                     §    §                 §    §       
  Segment profit*  $                      125    21.1 %    $      95    17.0 %  
                                                                                
_______________________
* Segment profit does not include amortization and certain other items.
§ Represents
an amount less than $0.5 million or 0.5%, as applicable.

Revenues from our International Markets segment in the third quarter of 2026
were $592 million, an increase of 6%
compared to the third quarter of 2025. In local currency terms, revenues
increased by 4% compared to the third quarter of 2025, mainly
due to higher revenues from our key innovative products AJOVY and AUSTEDO.

In the third quarter of 2026, revenues were positively impacted by exchange rate
fluctuations of $13 million, including hedging effects,
compared to the third quarter of 2025. Revenues in the third quarter of 2026
included $7 million from a positive hedging impact, compared
to $2 million in the third quarter of 2025, which are included in “Other” in the
table below.

Revenues by Major Products and Activities

The following table presents revenues for our International Markets segment by
major products and activities for the three months ended
September 30, 2026 and 2025:
                                                                                
                           Three months ended                                   
                           September                                            
                           30,                                      Percentage  
                           2026                                     Change      
                           (U.S.$ in millions)         2025         2026-2025   
 ────────────────────────────────────────────────────────────────────────────── 
  Generic products                                                              
  (including OTC and       $                    407    $     421    (3)%        
  biosimilars)                                                                  
  AJOVY                                          48           30    61%         
  AUSTEDO                                        24           17    42%         
  COPAXONE                                        8            8    8%          
  Other*                                        105           82    28%         
  Total                    $                    592    $     557    6%          
                                                                                
_______________________*Other revenues in the third quarters of 2026 and 2025
include the sale of certain product
rights.

Generic products revenues (including OTC and biosimilar products) in our
International Markets segment in the third
quarter of 2026 were $407 million, a decrease of 3% compared to the third
quarter of 2025. In local currency terms, revenues decreased
by 4%, mainly due to lower revenues from generic and OTC products in certain
markets including Ukraine.

AJOVYrevenues in our International Markets segment in the third quarter of 2026
were $48 million, an increase of
61% in both U.S. dollars and local currency terms compared to the third quarter
of 2025. This increase was mainly due to growth in multiple
markets. In April 2026, we announced a strategic partnership for the marketing
and distribution of AJOVY in China with Nuerogen (Zhuhai)
Pharmaceutical Company Ltd.

AUSTEDOrevenues in our International Markets segment in the third quarter of
2026 were $24 million, an increase of
42% compared to the third quarter of 2025. In local currency terms, revenue
increased by 34% compared to the third quarter of 2025, mainly
due to growth in China.

COPAXONE revenues in our International Markets segment in the third quarter of
2026 were $8 million, an increase of
8% compared to the third quarter of 2025.

International Markets Gross Profit

Gross profit from our International Markets segment in the third quarter of 2026
was $316 million, an increase of
14% compared to the third quarter of 2025.

Gross profit margin for our International Markets segment in the third quarter
of 2026 increased to 53.3%, compared
to 49.8% in the third quarter of 2025. This increase was mainly due to a
favorable mix of products, primarily attributed to higher revenues
from AJOVY and AUSTEDO, partially offset by lower revenues from generic
products, as discussed above.

International Markets Profit

Profit from our International Markets segment consists of revenues less cost of
sales, R&D expenses, S&M expenses, G&A
expenses and other expenses (income) related to this segment. Segment profit
does not include amortization and certain other items.

Profitfrom our International Markets segment in the third quarter of 2026 was
$125 million, an increase of 32%, compared
to the third quarter of 2025. This increase was mainly due to higher gross
profit, as discussed above.

Other Activities

We have other sources of revenues, primarily our distribution business in the
United States to third parties through Anda, the sale
of APIs to third parties, an out-licensing platform offering a portfolio of
products to other pharmaceutical companies through our affiliate
Medis, and certain contract manufacturing services. Our Other Activities are not
included in our United States, Europe or International
Markets segments described above.

In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda
is no longer reported under our United States segment.
As a result, from that date, Anda is reported as part of our Other Activities.
Prior period amounts were recast to reflect this change.

In 2024, we announced that we intend to divest our API business (including its
R&D, manufacturing and commercial activities) through
a sale. The intention to divest is in alignment with our Pivot to Growth
strategy, and Teva is conducting a sales process for this matter.
However, there can be no assurance regarding the ultimate timing or structure of
a potential divestiture or that a divestiture will be
completed at all.

Our revenues from Other Activities in the third quarter of 2026 were $613
million, an increase of 3% in both U.S. dollars and local
currency terms, compared to the third quarter of 2025.

Anda revenues from third-party products in the third quarter of 2026 were $401
million, an increase of 2%, compared to the third quarter
of 2025, mainly due to higher volumes. Anda, our distribution business in the
United States, operates independently and distributes generic
and innovative medicines and OTC pharmaceutical products from various
manufacturers to independent retail pharmacies, pharmacy retail
chains, hospitals and physician offices in the United States. Anda competes in
the distribution market by maintaining a broad portfolio
of products, competitive pricing and delivery throughout the United States.

API sales to third parties in the third quarter of 2026 were $115 million, a
decrease of 8% in both U.S. dollars and local currency
terms, compared to the third quarter of 2025. This decrease was mainly due to
lower demand resulting from market dynamics and temporary
supply challenges.

Revenues from additional other activities, mainly from Medis and certain
contract manufacturing services, were $98 million in the third
quarter of 2026, an increase of 21% in U.S. dollars, or 23% in local currency
terms compared to the third quarter of 2025, mainly due
to higher demand.

2026 Financial Outlook
                                                                                
  $                                                                             
  billions, except                  Prior        Updated  Key                   
  diluted EPS or as              Guidance       Guidance  Assumptions           
  noted                                                                         
                                                          Assume growth in      
  Revenues                 $16.5 - $16.85  $16.7 - $17.0  innovative            
                                                          products              
  AUSTEDO ($m)              2,450 - 2,600  2,550 - 2,650                        
  AJOVY ($m)                    850 - 870      930 - 960                        
  UZEDY ($m)                    270 - 290      290 - 310                        
                                                          Increase of $0.05B    
                                                          before updating       
  Operating Income*             3.8 - 4.0      3.8 - 3.9  guidance              
                                                          for $0.1B impact of   
                                                          acquired IPR&D        
                                                          charge                
  Adjusted EBITDA*            4.23 - 4.53    4.23 - 4.43                        
  Finance Expenses*                 ~$0.8          ~$0.8                        
  Tax Rate*                     20% - 23%      20% - 23%                        
                                                          Increase of $0.08 at  
                                                          midpoint before       
                                                          updating guidance     
  Diluted EPS* ($)            1.91 - 2.11    1.92 - 2.11  for                   
                                                          $0.07 impact of       
                                                          acquired IPR&D        
                                                          charge                
  Free Cash Flow*               2.0 - 2.4      2.1 - 2.4                        
  CAPEX                               0.5            0.5                        
                       Volatile swings in                                       
  Foreign Exchange      FX can negatively                                       
                       impact revenue and                                       
                                   income                                       
                                                                                
Financial guidance only assumes business development transactions closed as of
November 3, 2026.

Certain items above are non-GAAP financial measures. For more information, see
“Non-GAAP Financial Measures”
below. Free Cash Flow includes cash flow generated from operating activities net
of capital expenditures and deferred purchase price cash
component collected for securitized trade receivables.

Conference Call

Teva will host a conference call and live webcast along with a slide
presentation on Tuesday, November 3, 2026 at 8:00 a.m. ET
to discuss its third quarter 2026 financial results and overall business
environment.

A question & answer session will follow.

In order to participate, please register in advance to obtain a local or
toll‐free phone number and your personal pin.

A live webcast of the call will be available on Teva's website at:

Following the conclusion of the call, a replay of the webcast will be available
within 24 hours on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a
leading innovative biopharmaceutical company, enabled
by a world-class generics business. For over 120 years, Teva’s commitment to
bettering health has never wavered. From innovating
in the fields of neuroscience and immunology to providing complex generic
medicines, biosimilars and pharmacy brands worldwide, Teva is
dedicated to addressing patients’ needs, now and in the future. At Teva, We Are
All In For Better Health. To learn more about how,
visit .

Some amounts in this press release may not add up due to rounding. All
percentages have been calculated using unrounded amounts.

Non-GAAP Financial Measures

This press release contains certain financial information that differs from what
is reported under accounting principles generally
accepted in the United States (“GAAP”). These non-GAAP financial measures,
including, but not limited to, non-GAAP operating
income, non-GAAP operating margin, non-GAAP gross profit, non-GAAP gross profit
margin, Adjusted EBITDA, free cash flow, non-GAAP tax
rate, non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS,
are presented in order to facilitate investors' understanding
of our business. We utilize certain non-GAAP financial measures to evaluate
performance in conjunction with other performance metrics.
The following are examples of how we utilize the non-GAAP measures: our
management and board of directors use the non-GAAP measures to
evaluate our operational performance and, to compare our results against work
plans and budgets, and ultimately to evaluate the performance
of management; our annual budgets are prepared on a non-GAAP basis; and senior
management’s annual compensation is derived, in part,
using these non-GAAP measures. See the attached tables for a reconciliation of
the GAAP results to the adjusted non-GAAP measures. Investors
should consider non-GAAP financial measures in addition to, and not as
replacements for, or superior to, measures of financial performance
prepared in accordance with GAAP. We are not providing the most comparable
forward-looking GAAP measures for non-GAAP metrics included
in our financial outlook or a quantitative reconciliation of forward-looking
non-GAAP financial measures to the most directly comparable
GAAP measures because we are unable to predict with reasonable certainty the
ultimate outcome of certain significant items including,
but not limited to, the amortization of purchased intangible assets, legal
settlements and loss contingencies, impairment of long-lived
assets and goodwill impairment, without unreasonable effort. These items are
uncertain, depend on various factors, and could be material
to our results computed in accordance with GAAP.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995,
which are based on management’s current beliefs and expectations and are subject
to substantial risks and uncertainties, both known
and unknown, that could cause our future results, performance or achievements to
differ significantly from that expressed or implied by
such forward-looking statements. You can identify these forward-looking
statements by the use of words such as “should,” "will",
“expect,” “aim”, “anticipate,” “estimate,” “target,” “may,” “project,”
“guidance,” “intend,” “plan,” “believe”, “outlook”, “transition”
and other words and terms of similar meaning and expression in connection with
any discussion of future operating financial performance
or development. Important factors that could cause or contribute to such
differences include risks relating to:

other factors discussed in this press release, in our Quarterly Report on Form
10-Q for the third quarter of 2026 and in our Annual
Report on Form 10-K for the year ended December 31, 2025, including in the
sections captioned “Risk Factors” and “Cautionary
Note Regarding Forward-Looking Statements.“ Forward-looking statements speak
only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking statements or other
information contained herein, whether as a result of
new information, future events or otherwise. You are cautioned not to put undue
reliance on these forward-looking statements.
                                                                                
  Consolid…                                                                     
  Statemen…                                                                     
  of Income                                                                     
  (U.S.                                                                         
  dollars                                                                       
  in                                                                            
  millions,                                                                     
  except                                                                        
  share and                                                                     
  per share                                                                     
  data)                                                                         
  (Unaudit…                                                                     
                               Three                         Nine               
                              months                       months               
                               ended                        ended               
                           September                    September               
                                 30,                          30,               
                                2026        2025             2026         2025  
  Net                 $        4,395    $  4,480    $      12,519    $  12,547  
  revenues                                                                      
  Cost of                      1,955       2,176            5,954        6,264  
  sales                                                                         
  Gross                        2,440       2,304            6,565        6,282  
  profit                                                                        
  Research                                                                      
  and                            297         256            1,489          746  
  developm…                                                                     
  expenses                                                                      
  Selling                                                                       
  and                            709         656            2,122        1,933  
  marketing                                                                     
  expenses                                                                      
  General                                                                       
  and                            298         317              919          920  
  administ…                                                                     
  expenses                                                                      
  Intangib…                                                                     
  assets                          24          64               54          227  
  impairme…                                                                     
  Other                                                                         
  asset                                                                         
  impairme…                      264          62              438          272  
  restruct…                                                                     
  and other                                                                     
  items                                                                         
  Legal                                                                         
  settleme…                      202          60              504          312  
  and loss                                                                      
  continge…                                                                     
  Other                                                                         
  loss                           -68           7              -96           15  
  (income)                                                                      
  Operating                                                                     
  income                         714         882            1,135        1,857  
  (loss)                                                                        
  Financial                                                                     
  expenses,                      414         237              854          714  
  net                                                                           
  Income                                                                        
  (loss)                                                                        
  before                         300         646              282        1,143  
  income                                                                        
  taxes                                                                         
  Income                                                                        
  taxes                           66         214              254          210  
  (benefit)                                                                     
  Share in                                                                      
  (profits)                                                                     
  losses of                        *          -2                *           -4  
  associat…                                                                     
  companie…                                                                     
  net                                                                           
  Net                                                                           
  income                         234         434               27          937  
  (loss)                                                                        
  Net                                                                           
  income                                                                        
  (loss)                                                                        
  attribut…                                                                     
  to                               1           1                1            7  
  redeemab…                                                                     
  and                                                                           
  non-rede…                                                                     
  non-cont…                                                                     
  interest                                                                      
  Net                                                                           
  income                                                                        
  (loss)                         233         433               26          930  
  attribut…                                                                     
  to Teva                                                                       
  Earnings                                                                      
  (loss)                                                                        
  per share  Basic    $         0.20    $   0.38    $        0.02    $    0.81  
  attribut…                                                                     
  to Teva:                                                                      
             Diluted  $         0.20    $   0.37    $        0.02    $    0.80  
  Weighted                                                                      
  average                                                                       
  number of  Basic             1,166       1,147            1,162        1,144  
  shares                                                                        
  (in                                                                           
  millions…                                                                     
             Diluted           1,183       1,164            1,180        1,160  
  Non-GAAP                                                                      
  net                                                                           
  income                                                                        
  attribut…                                                                     
  to Teva                      1,013         910            1,655        2,281  
  for                                                                           
  diluted                                                                       
  earnings                                                                      
  per                                                                           
  share:**                                                                      
  Non-GAAP                                                                      
  earnings                                                                      
  per share  Diluted  $         0.86    $   0.78    $        1.40    $    1.97  
  attribut…                                                                     
  to                                                                            
  Teva:**                                                                       
  Non-GAAP                                                                      
  average                                                                       
  number of  Diluted           1,183       1,164            1,180        1,160  
  shares                                                                        
  (in                                                                           
  millions…                                                                     
  Amounts                                                                       
  may not                                                                       
  add                                                                           
  up due to                                                                     
  rounding.                                                                     
  *                                                                             
  Represen…                                                                     
  an amount                                                                     
  less than                                                                     
  $0.5                                                                          
  million.                                                                      
  ** See                                                                        
  reconcil…                                                                     
  attached.                                                                     
                                                                                
                                                                                
  CONSOLIDATED BALANCE SHEETS                                                   
  (U.S. dollars in millions,                                                    
  except for share data)                                                        
  (Unaudited)                                                                   
  ASSETS                         September 30,            December 31,          
  Current assets:                2026                     2025                  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash equivalents      $               4,085    $              3,556  
  Accounts receivables, net of                                                  
  allowance for credit losses                                                   
  of $71 million and $81                                                        
  million                                        3,837                   3,709  
  as of September 30, 2026 and                                                  
  December 31, 2025,                                                            
  respectively.                                                                 
  Inventories                                    3,173                   3,179  
  Prepaid expenses                               1,014                   1,122  
  Other current assets                             658                     539  
  Assets held for sale                           1,836                   1,842  
  Total current assets                          14,602                  13,946  
  Deferred income taxes                          2,057                   2,191  
  Other non-current assets                         269                     405  
  Property, plant and                            3,747                   4,080  
  equipment, net                                                                
  Operating lease right-of-use                     321                     345  
  assets, net                                                                   
  Identifiable intangible                        3,303                   3,781  
  assets, net                                                                   
  Goodwill                                      15,742                  16,000  
  Total assets                   $              40,042    $             40,748  
  LIABILITIES AND EQUITY                                                        
  Current liabilities:                                                          
  Short-term debt                $               4,038    $              1,820  
  Sales reserves and allowances                  3,955                   4,143  
  Accounts payables                              2,551                   2,531  
  Employee-related obligations                     588                     739  
  Accrued expenses                               2,962                   2,687  
  Other current liabilities                      1,036                   1,182  
  Liabilities held for sale                        296                     354  
  Total current liabilities                     15,425                  13,456  
  Long-term liabilities:                                                        
  Deferred income taxes                            263                     296  
  Other taxes and long-term                      3,422                   3,808  
  liabilities                                                                   
  Senior notes and loans                        12,680                  14,986  
  Operating lease liabilities                      266                     288  
  Total long-term liabilities                   16,632                  19,379  
  Equity:                                                                       
  Teva shareholders’ equity:                     7,979                   7,910  
  Non-controlling interests                          5                       4  
  Total equity                                   7,984                   7,914  
  Total liabilities and equity   $              40,042    $             40,748  
  Amounts may not add up due to                                                 
  rounding.                                                                     
                                                                                
                                                                                
  TEVA                                                                          
  PHARMACEUTI…                                                                  
  INDUSTRIES                                                                    
  LIMITED                                                                       
  CONSOLIDATED                                                                  
  STATEMENTS                                                                    
  OF CASH                                                                       
  FLOWS                                                                         
  (U.S.                                                                         
  dollars in                                                                    
  millions)                                                                     
  (Unaudited)   Three months                    Nine months                     
  Operating     ended                           ended                           
  activities:   September 30,    2026   2025    September 30,     2026    2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Net income    $                 234    434    $                   27     937  
  (loss)                                                                        
  Adjustments                                                                   
  to reconcile                                                                  
  net income                                                                    
  (loss) to                                                                     
  net cash                                                                      
  provided by                                                                   
  operations:                                                                   
  Depreciation                                                                  
  and                             245    249                       725     742  
  amortization                                                                  
  Impairment                                                                    
  of                                                                            
  long-lived                      228     79                       350     255  
  assets and                                                                    
  assets held                                                                   
  for sale                                                                      
  Acquired                                                                      
  in-process                       23     17                       785      52  
  research and                                                                  
  development*                                                                  
  Net change                                                                    
  in operating                   -682   -578                    -1,523  -1,647  
  assets and                                                                    
  liabilities                                                                   
  Deferred                                                                      
  income taxes                                                                  
  – net and                        53    107                        56     -76  
  uncertain                                                                     
  tax                                                                           
  positions                                                                     
  Stock-based                      38     34                       121     106  
  compensation                                                                  
  Loss on                                                                       
  extinguishm…                    224      -                       224       -  
  of debt                                                                       
  Other items                     -53     27                       -65     122  
  Net loss                                                                      
  (gain) from                                                                   
  sale of                                                                       
  business                        -69      -                       -89       -  
  and                                                                           
  long-lived                                                                    
  assets                                                                        
  Net cash                                                                      
  provided by                                                                   
  (used in)                       241    369                       612     491  
  operating                                                                     
  activities                                                                    
  Investing                                                                     
  activities:                                                                   
  Beneficial                                                                    
  interest                                                                      
  collected in                                                                  
  exchange for                    327    274                       992     932  
  securitized                                                                   
  accounts                                                                      
  receivables                                                                   
  Purchases of                                                                  
  property,                                                                     
  plant and                                                                     
  equipment                      -120   -136                      -393    -359  
  and                                                                           
  intangible                                                                    
  assets                                                                        
  Proceeds                                                                      
  from sale of                                                                  
  businesses                       47      8                        93      34  
  and                                                                           
  long-lived                                                                    
  assets, net                                                                   
  Purchases of                                                                  
  in-process                      -46    -12                      -747     -41  
  research and                                                                  
  development*                                                                  
  Other                                                                         
  investing                         2      1                         3       6  
  activities                                                                    
  Net cash                                                                      
  provided by                                                                   
  (used in)                       210    135                       -52     572  
  investing                                                                     
  activities                                                                    
  Financing                                                                     
  activities:                                                                   
  Repayment of                                                                  
  senior notes                                                                  
  and loans                                                                     
  and                          -4,883   -444                    -4,906  -4,112  
  other                                                                         
  long-term                                                                     
  liabilities                                                                   
  Proceeds                                                                      
  from senior                                                                   
  notes, net                    4,845     -7                     4,845   2,298  
  of                                                                            
  issuance                                                                      
  costs                                                                         
  Purchase of                                                                   
  shares from                                                                   
  redeemable                                                                    
  and                               -      -                         -     -38  
  non-redeema…                                                                  
  non-control…                                                                  
  interests                                                                     
  Dividends                                                                     
  paid to                                                                       
  redeemable                                                                    
  and                               -      -                         -    -340  
  non-redeema…                                                                  
  non-control…                                                                  
  interests                                                                     
  Other                                                                         
  financing                        43     -2                        78       1  
  activities                                                                    
  Net cash                                                                      
  provided by                                                                   
  (used in)                         6   -453                        18  -2,191  
  financing                                                                     
  activities                                                                    
  Effect of                                                                     
  exchange                                                                      
  rate changes                    -27     -9                       -49      31  
  on cash                                                                       
  and cash                                                                      
  equivalents                                                                   
  Net change                                                                    
  in cash and                     430     42                       529  -1,097  
  cash                                                                          
  equivalents                                                                   
  Balance of                                                                    
  cash and                                                                      
  cash                                                                          
  equivalents                   3,655  2,161    $                3,556   3,300  
  at                                                                            
  beginning of                                                                  
  period                                                                        
  Balance of                                                                    
  cash and                                                                      
  cash                                                                          
  equivalents   $               4,085  2,203    $                4,085   2,203  
  at                                                                            
  end of                                                                        
  period                                                                        
  Non-cash                                                                      
  financing                                                                     
  and                                                                           
  investing                                                                     
  activities:                                                                   
  Beneficial                                                                    
  interest                                                                      
  obtained in                                                                   
  exchange      $                 253    296    $                  859     937  
  for                                                                           
  securitized                                                                   
  accounts                                                                      
  receivables                                                                   
  Receivable                                                                    
  for sale of                      90      -                        90       -  
  long-lived                                                                    
  assets                                                                        
  * In the                                                                      
  first nine                                                                    
  months of                                                                     
  2026, mainly                                                                  
  related to                                                                    
  the                                                                           
  acquisition                                                                   
  of Emalex                                                                     
  and its                                                                       
  primary                                                                       
  asset                                                                         
  ecopipam                                                                      
  (EBS-101).                                                                    
  Amounts may                                                                   
  not add up                                                                    
  due to                                                                        
  rounding.                                                                     
  The                                                                           
  accompanying                                                                  
  notes are an                                                                  
  integral                                                                      
  part of the                                                                   
  financial                                                                     
  statements.                                                                   
                                                                                
                                                                                
               ($ in                                                            
               millions                                                         
               except per                                                       
               share                                                            
               amounts)                                                         
               Net income                                                       
               (Loss)                                                           
               attributable                                                     
               to Teva                                                          
               Increase                                                         
               (decrease)                                                       
               for excluded                                                     
               items:                                                           
               Amortization                                                     
               of purchased                                                     
               intangible                                                       
               assets                                                           
               Legal                                                            
               settlements                                                      
               and loss                                                         
               contingenci…                                                     
               Impairment                                                       
               of                                                               
               long-lived                                                       
               assets(2)                                                        
               Restructuri…                                                     
               costs(3)                                                         
               Equity                                                           
               compensation           Three                                     
               Contingent            months                Nine months          
               considerati…           ended                      ended          
               Financial          September                  September          
               expenses(4)              30,                        30,          
               Other                   2026    2025               2026    2025  
  Reconcilia…  non-GAAP                 233     433                 26     930  
  of net       items(5)                 139     144                415     436  
  income       Correspondi…             201      60                503     309  
  (loss)       tax effects              228      79                350     255  
  attributab…  and unusual               58      29                121     196  
  to Teva      tax items(6)              38      34                121     106  
  to Non-GAAP  Non-GAAP net               2      16                 25      46  
  net income   income                   235       7                256      58  
  (loss)       attributable              14      51                 55     170  
  attributab…  to Teva                (134)      58              (216)   (225)  
  to Teva      Non-GAAP tax           1,013     910              1,655   2,281  
  (Unaudited)  rate(7)               16.5 %  14.7 %             22.1 %  16.0 %  
 ────────────────────────────────────────────────────────────────────────────── 
               GAAP diluted                                                     
               earnings                                                         
               (loss) per    $         0.20    0.37    $          0.02    0.80  
               share                                                            
               attributable                                                     
               to Teva                                                          
               EPS                     0.66    0.41               1.38    1.16  
               difference(…                                                     
               Non-GAAP                                                         
               diluted EPS   $         0.86    0.78    $          1.40    1.97  
               attributable                                                     
               to Teva(8)                                                       
               Non-GAAP                                                         
               average                                                          
               number of              1,183   1,164              1,180   1,160  
               shares (in                                                       
               millions)(8)                                                     
               For the                                                          
               three months                                                     
               ended                                                            
               September                                                        
               30, 2026,                                                        
               adjustments                                                      
               for legal                                                        
               settlements                                                      
               and loss                                                         
               contingenci…                                                     
               mainly                                                           
               consisted of                                                     
               (a) an                                                           
               update to                                                        
               the                                                              
               estimated                                                        
               provision                                                        
               recorded in                                                      
               connection                                                       
               with one of                                                      
               the                                                              
               Company’s                                                        
               ongoing                                                          
               antitrust                                                        
               litigations                                                      
               in the                                                           
               amount of                                                        
               $133                                                             
               million, and                                                     
               (b) an                                                           
               update to                                                        
               the                                                              
               estimated                                                        
               settlement                                                       
               provision                                                        
               for the                                                          
               opioid                                                           
               cases                                                            
               (mainly the                                                      
               effect of                                                        
               the passage                                                      
               of time on                                                       
               the net                                                          
               present                                                          
               value of the                                                     
               discounted                                                       
               payments) in                                                     
               the amount                                                       
               of $35                                                           
               million.                                                         
               For the nine                                                     
               months ended                                                     
               September                                                        
               30, 2026,                                                        
               adjustments                                                      
               for legal                                                        
               settlements                                                      
               and loss                                                         
               contingenci…                                                     
               mainly                                                           
               consisted of                                                     
               (a) an                                                           
               estimated                                                        
               provision                                                        
               recorded in                                                      
               connection                                                       
               with one of                                                      
               the                                                              
               Company’s                                                        
               ongoing                                                          
               antitrust                                                        
               litigations                                                      
               in the                                                           
               amount of                                                        
               $250                                                             
               million, and                                                     
               (b)                                                              
  (1)          an update to                                                     
               the                                                              
               estimated                                                        
               settlement                                                       
               provision                                                        
               for the                                                          
               opioid cases                                                     
               (mainly the                                                      
               effect of                                                        
               the passage                                                      
               of time on                                                       
               the net                                                          
               present                                                          
               value                                                            
               of the                                                           
               discounted                                                       
               payments) in                                                     
               the amount                                                       
               of $132                                                          
               million. For                                                     
               the three                                                        
               and nine                                                         
               months ended                                                     
               September                                                        
               30, 2025,                                                        
               adjustments                                                      
               of                                                               
               legal                                                            
               settlements                                                      
               and loss                                                         
               contingenci…                                                     
               mainly                                                           
               consisted of                                                     
               (a) an                                                           
               update to                                                        
               the                                                              
               estimated                                                        
               settlement                                                       
               provision                                                        
               for the                                                          
               opioid cases                                                     
               (mainly the                                                      
               effect of                                                        
               the passage                                                      
               of time on                                                       
               the net                                                          
               present                                                          
               value of the                                                     
               discounted                                                       
               payments) in                                                     
               the amount                                                       
               of $42                                                           
               million and                                                      
               $139                                                             
               million,                                                         
               respectivel…                                                     
               and (b) an                                                       
               update to                                                        
               the                                                              
               estimated                                                        
               provision                                                        
               recorded for                                                     
               the claims                                                       
               brought by                                                       
               attorneys                                                        
               general                                                          
               representing                                                     
               states and                                                       
               territories                                                      
               throughout                                                       
               the U.S. in                                                      
               the generic                                                      
               drug                                                             
               antitrust                                                        
               litigation                                                       
               in the                                                           
               amount of                                                        
               $55 million.                                                     
               The expense                                                      
               for the                                                          
               three and                                                        
               nine months                                                      
               ended                                                            
               September                                                        
               30, 2026,                                                        
               mainly                                                           
               consisted of                                                     
               (a)                                                              
               impairment                                                       
               charges in                                                       
               connection                                                       
               with several                                                     
               manufacturi…                                                     
               facilities                                                       
               in Europe in                                                     
               the amount                                                       
               of $140                                                          
               million and                                                      
               $210                                                             
               million,                                                         
               respectivel…                                                     
               and (b)                                                          
               impairment                                                       
               charges in                                                       
               connection                                                       
               with the                                                         
               held for                                                         
               sale                                                             
               measurement                                                      
               of the API                                                       
               business                                                         
               (including                                                       
               its R&D,                                                         
               manufacturi…                                                     
  (2)          and                                                              
               commercial                                                       
               activities),                                                     
               which                                                            
               includes an                                                      
               impact                                                           
               related to                                                       
               the expected                                                     
               gain from                                                        
               reclassific…                                                     
               of                                                               
               currency                                                         
               translation                                                      
               adjustments                                                      
               in the                                                           
               amount of                                                        
               $49 million                                                      
               and $66                                                          
               million,                                                         
               respectivel…                                                     
               For the nine                                                     
               months ended                                                     
               September                                                        
               30, 2025,                                                        
               the                                                              
               adjustment                                                       
               for                                                              
               impairment                                                       
               of                                                               
               long-lived                                                       
               assets was                                                       
               mainly                                                           
               related to                                                       
               intangible                                                       
               assets in                                                        
               the U.S. and                                                     
               Europe.                                                          
               In the nine                                                      
               months ended                                                     
               September                                                        
               30, 2026 and                                                     
               2025, Teva                                                       
               recorded                                                         
               restructuri…                                                     
               expenses of                                                      
               $121 million                                                     
               and $196                                                         
               million,                                                         
               respectivel…                                                     
               primarily                                                        
               related to                                                       
               optimization                                                     
  (3)          activities                                                       
               in                                                               
               connection                                                       
               with Teva’s                                                      
               Transformat…                                                     
               programs                                                         
               related to                                                       
               Teva’s                                                           
               global                                                           
               organization                                                     
               and                                                              
               operations                                                       
               mainly                                                           
               through                                                          
               headcount                                                        
               reduction.                                                       
               In the three                                                     
               and nine                                                         
               months ended                                                     
               September                                                        
               30, 2026,                                                        
               Teva                                                             
               recorded                                                         
  (4)          $224                                                             
               million of                                                       
               finance                                                          
               expenses                                                         
               related to a                                                     
               loss on                                                          
               extinguishm…                                                     
               of debt.                                                         
               Other                                                            
               non-GAAP                                                         
               items                                                            
               include                                                          
               other                                                            
               exceptional                                                      
               items that                                                       
               we believe                                                       
               are                                                              
               sufficiently                                                     
               large that                                                       
               their                                                            
               exclusion is                                                     
               important to                                                     
               facilitate                                                       
               an                                                               
  (5)          understandi…                                                     
               of trends in                                                     
               our                                                              
               financial                                                        
               results,                                                         
               primarily                                                        
               related                                                          
               to material                                                      
               litigation                                                       
               fees,                                                            
               rationaliza…                                                     
               of our                                                           
               plants,                                                          
               accelerated                                                      
               depreciation                                                     
               and other                                                        
               unusual                                                          
               events.                                                          
               Adjustments                                                      
               for                                                              
               correspondi…                                                     
               tax effects                                                      
               and unusual                                                      
               tax items                                                        
               exclusively                                                      
               consisted of                                                     
               the tax                                                          
               impact                                                           
               directly                                                         
  (6)          attributable                                                     
               to the                                                           
               pre-tax                                                          
               items that                                                       
               are excluded                                                     
               from                                                             
               non-GAAP net                                                     
               income                                                           
               included in                                                      
               the other                                                        
               adjustments                                                      
               to this                                                          
               table.                                                           
               Non-GAAP tax                                                     
               rate is tax                                                      
               expenses                                                         
               (benefit)                                                        
               excluding                                                        
               the impact                                                       
               of non-GAAP                                                      
               tax                                                              
               adjustments                                                      
               presented                                                        
               above as a                                                       
               percentage                                                       
               of income                                                        
               (loss)                                                           
               before                                                           
               income taxes                                                     
               excluding                                                        
               the impact                                                       
               of non-GAAP                                                      
               adjustments                                                      
               presented                                                        
               above. Our                                                       
               non-GAAP tax                                                     
               rate in the                                                      
               nine months                                                      
               ended                                                            
               September                                                        
               30, 2026 was                                                     
               mainly                                                           
               affected by                                                      
               an                                                               
               unfavorable                                                      
               tax impact                                                       
  (7)          of a                                                             
               non-deducti…                                                     
               acquired                                                         
               IPR&D charge                                                     
               related to                                                       
               the                                                              
               acquisition                                                      
               of Emalex                                                        
               and its                                                          
               primary                                                          
               asset                                                            
               ecopipam                                                         
               (EBS-101),                                                       
               the                                                              
               generation                                                       
               of profits                                                       
               in                                                               
               various                                                          
               jurisdictio…                                                     
               in which tax                                                     
               rates are                                                        
               different                                                        
               than the                                                         
               Israeli tax                                                      
               rate, and                                                        
               other                                                            
               infrequent                                                       
               or                                                               
               non-recurri…                                                     
               items, such                                                      
               as                                                               
               internal                                                         
               legal                                                            
               entities                                                         
               reorganizat…                                                     
               EPS                                                              
               difference                                                       
               and diluted                                                      
               non-GAAP EPS                                                     
               are                                                              
               calculated                                                       
               by dividing                                                      
               our                                                              
  (8)          non-GAAP net                                                     
               income                                                           
               attributable                                                     
               to Teva by                                                       
               our non-GAAP                                                     
               diluted                                                          
               weighted                                                         
               average                                                          
               number of                                                        
               shares.                                                          
                                                                                
                                                                                
  Reconciliation                                                                
  of gross profit                                                               
  to                                                                            
  Non-GAAP gross                                                                
  profit                                                                        
  (Unaudited)                                                                   
                            Three months              Nine months ended         
                                   ended                                        
                           September 30,                  September 30,         
  ($ in millions)                   2026   2025                    2026   2025  
  Gross profit      $              2,440  2,304    $              6,565  6,282  
  Gross profit                     55.5%  51.4%                   52.4%  50.1%  
  margin                                                                        
  Increase                                                                      
  (decrease) for                                                                
  excluded items:                                                               
  (1)                                                                           
  Amortization of                                                               
  purchased                          129    134                     387    406  
  intangible                                                                    
  assets                                                                        
  Equity                               6      6                      18     17  
  compensation                                                                  
  Other non-GAAP                       5     32                      11    101  
  items                                                                         
  Non-GAAP gross    $              2,580  2,475    $              6,981  6,807  
  profit                                                                        
  Non-GAAP gross                                                                
  profit margin                    58.7%  55.3%                   55.8%  54.3%  
  (2)                                                                           
  (1) For further                                                               
  explanations,                                                                 
  refer to the                                                                  
  footnotes under                                                               
  the                                                                           
  "Reconciliation                                                               
  of net income                                                                 
  (loss)                                                                        
  attributable to                                                               
  Teva to Non-GAAP                                                              
  net income                                                                    
  (loss)                                                                        
  attributable to                                                               
  Teva" table.                                                                  
  (2) Non-GAAP                                                                  
  gross profit                                                                  
  margin is                                                                     
  non-GAAP gross                                                                
  profit as a                                                                   
  percentage                                                                    
  of revenue.                                                                   
                                                                                
                                                                                
  Reconciliation                                                                
  of operating                                                                  
  income (loss)                                                                 
  to Non-GAAP                                                                   
  operating                                                                     
  income (loss)                                                                 
  (Unaudited)                                                                   
                           Three months                    Nine months          
                                  ended                          ended          
                          September 30,                  September 30,          
  ($ in millions)                  2026    2025                   2026    2025  
  Operating        $                714     882    $             1,135   1,857  
  income (loss)                                                                 
  Operating                      16.2 %  19.7 %                  9.1 %  14.8 %  
  margin                                                                        
  Increase                                                                      
  (decrease) for                                                                
  excluded items:                                                               
  (1)                                                                           
  Amortization of                                                               
  purchased                         139     144                    415     436  
  intangible                                                                    
  assets                                                                        
  Legal                                                                         
  settlements and                   201      60                    503     309  
  loss                                                                          
  contingencies                                                                 
  Impairment of                                                                 
  long-lived                        228      79                    350     255  
  assets                                                                        
  Restructuring                      58      29                    121     196  
  costs                                                                         
  Equity                             38      34                    121     106  
  compensation                                                                  
  Contingent                          2      16                     25      46  
  consideration                                                                 
  Loss (gain) on                                                                
  sale of                            -1       6                     -5      19  
  business                                                                      
  Other non-GAAP                     15      45                     60     149  
  items                                                                         
  Non-GAAP                                                                      
  operating        $              1,393   1,294    $             2,724   3,373  
  income (loss)                                                                 
  Non-GAAP                                                                      
  operating                      31.7 %  28.9 %                 21.8 %  26.9 %  
  margin(2)                                                                     
  (1) For further                                                               
  explanations,                                                                 
  refer to the                                                                  
  footnotes under                                                               
  the                                                                           
  "Reconciliation                                                               
  of net income                                                                 
  (loss)                                                                        
  attributable to                                                               
  Teva to                                                                       
  Non-GAAP net                                                                  
  income (loss)                                                                 
  attributable to                                                               
  Teva" table.                                                                  
  (2) Non-GAAP                                                                  
  operating                                                                     
  margin is                                                                     
  Non-GAAP                                                                      
  operating                                                                     
  income                                                                        
  as a percentage                                                               
  of revenues.                                                                  
                                                                                
                                                                                
  Reconcilia…                                                                   
  of net                                                                        
  income                                                                        
  (loss) to                                                                     
  adjusted                                                                      
  EBITDA                                                                        
  (Unaudited)                                                                   
                                 Three months               Nine months         
                                        ended                     ended         
                                September 30,                 September         
                                                                    30,         
  ($ in                                  2026   2025               2026   2025  
  millions)                                                                     
  Net income                 $            234    434    $            27    937  
  (loss)                                                                        
  Increase                                                                      
  (decrease)                                                                    
  for                                                                           
  excluded                                                                      
  items:(1)                                                                     
               Financial                  414    237                854    714  
               expenses                                                         
               Income taxes                66    214                254    210  
               Share in                                                         
               profits                                                          
               (losses) of                  §     -2                  §     -4  
               associated                                                       
               companies                                                        
               –net                                                             
               Depreciation               106    105                311    306  
               Amortization               139    144                415    436  
  EBITDA                                  959  1,131              1,861  2,599  
               Legal                                                            
               settlements                201     60                503    309  
               and loss                                                         
               contingenci…                                                     
               Impairment                                                       
               of long                    228     79                350    255  
               lived assets                                                     
               Restructuri…                58     29                121    196  
               costs                                                            
               Equity                      38     34                121    106  
               compensation                                                     
               Contingent                   2     16                 25     46  
               considerati…                                                     
               Loss (Gain)                                                      
               on sale of                  -1      6                 -5     19  
               Business                                                         
               Other                                                            
               non-GAAP                    12     40                 50    137  
               items                                                            
  Adjusted                   $          1,496  1,394    $         3,025  3,668  
  EBITDA                                                                        
  (1) For                                                                       
  further                                                                       
  explanatio…                                                                   
  refer to                                                                      
  the                                                                           
  footnotes                                                                     
  under                                                                         
  the                                                                           
  "Reconcili…                                                                   
  of net                                                                        
  income                                                                        
  (loss)                                                                        
  attributab…                                                                   
  to Teva to                                                                    
  Non-GAAP                                                                      
  net income                                                                    
  (loss)                                                                        
  attributab…                                                                   
  to Teva"                                                                      
  table.                                                                        
  §                                                                             
  Represents                                                                    
  an amount                                                                     
  of less                                                                       
  than $0.5                                                                     
  million.                                                                      
                                                                                
                                                                                
     U…                                               In…                       
     S…                     E…                        Ma…                       
     T…                     T…                        Th…                       
     m…                     m…                        mo…                       
     e…                     e…                        en…                       
     S…                     S…                        Se…                       
     3…                     3…                        30,                       
     2…                     2…                        20…                       
     (…                     (…                        (U…                       
  …  $                      $                         $                         
  …  in                     in                        in                        
  …  m…        2…           m…           2…           mi…           20…         
 ────────────────────────────────────────────────────────────────────────────── 
  …  $   1…        $  2…        $  1…        $  1…         $  5…         $  5…  
  …                                                                             
  …      4…           6…           5…           5…            2…            2…  
  …                                                                             
  …      1…           1…           7…           6…            3…            2…  
  …                                                                             
  …      1…           1…           62           62            31            26  
  …                                                                             
  …      3…           2…           2…           2…            1…            1…  
  …                                                                             
  …      1…           1…           64           75            34            36  
  …                                                                             
  …       §           -3            §            §             §             §  
  …  $   7…        $  9…        $  4…        $  3…         $  1…         $  95  
  …                                                                             
  *                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  §                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
                                                                                
                                                                                
      Un…                                                                       
      St…                                               Int…                    
      Ni…                     Eur…                      Mar…                    
      mo…                     Nine                      Nine                    
      en…                     mon…                      mon…                    
      Se…                     end…                      end…                    
      30,                     Sep…                      Sep…                    
      20…                     30,                       30,                     
      (U…                     2026                      2026                    
  S…  $                       (U.…                      (U.…                    
  I…  in                      $ in                      $ in                    
  U…  mi…         20…         mil…         2025         mil…         2025       
 ────────────────────────────────────────────────────────────────────────────── 
  R…  $    5,…    $    5,…    $     3,…    $     3,…    $     1,…    $     1,…  
  C…                                                                            
  of       1,…         1,…          1,…          1,…          823          835  
  s…                                                                            
  G…       3,…         3,…          2,…          2,…          843          799  
  p…                                                                            
  R…       1,…         467          159          181           80           75  
  e…                                                                            
  S…       898         741          648          652          370          353  
  e…                                                                            
  G…       307         319          203          210          111          107  
  e…                                                                            
  O…        -9          -1           -3            §           -8           -3  
  i…                                                                            
  S…  $    1,…    $    2,…    $     1,…    $     996    $     289    $     266  
  p…                                                                            
  *                                                                             
  S…                                                                            
  p…                                                                            
  d…                                                                            
  n…                                                                            
  i…                                                                            
  a…                                                                            
  a…                                                                            
  c…                                                                            
  o…                                                                            
  i…                                                                            
  §                                                                             
  R…                                                                            
  an                                                                            
  a…                                                                            
  l…                                                                            
  t…                                                                            
  $…                                                                            
  m…                                                                            
                                                                                
                                                                                
  Reconciliation of our segment profit  Three months ended                      
  to consolidated income (loss) before  September 30,                           
  income taxes                          (U.S.$ in millions)   2026        2025  
 ────────────────────────────────────────────────────────────────────────────── 
  United States profit                  $                      791    $    927  
  Europe profit                                                420         303  
  International Markets profit                                 125          95  
  Total reportable segment profit                            1,336       1,325  
  Profit (loss) of other activities                             57         -31  
  Amounts not allocated to segments:                                            
  Amortization                                                 139         144  
  Other asset impairments,                                                      
  restructuring                                                264          62  
  and other items                                                               
  Intangible asset impairments                                  24          64  
  Legal settlements and loss                                   201          60  
  contingencies                                                                 
  Other unallocated amounts                                     51          82  
  Consolidated operating income (loss)                         714         882  
  Financial expenses - net                                     414         237  
  Consolidated income (loss) before                                             
  income                                $                      300    $    646  
  taxes                                                                         
                                                                                
                                                                                
                              Nine months ended                                 
  Reconciliation of our       September 30,                                     
  segment profit              September 30,                                     
  to consolidated income      2026                                              
  (loss) before income taxes  (U.S.$ in millions)                  2025         
 ────────────────────────────────────────────────────────────────────────────── 
  United States profit        $                           1,222    $     2,143  
  Europe profit                                           1,188            996  
  International Markets                                     289            266  
  profit                                                                        
  Total reportable segment                                2,699          3,405  
  profit                                                                        
  Profit (loss) of other                                     25            -32  
  activities                                                                    
  Amounts not allocated to                                                      
  segments:                                                                     
  Amortization                                              415            436  
  Other asset impairments,                                                      
  restructuring                                             438            272  
  and other items                                                               
  Intangible asset                                           54            227  
  impairments                                                                   
  Legal settlements and loss                                503            309  
  contingencies                                                                 
  Other unallocated amounts                                 179            272  
  Consolidated operating                                  1,135          1,857  
  income (loss)                                                                 
  Financial expenses - net                                  854            714  
  Consolidated income (loss)                                                    
  before income               $                             282    $     1,143  
  taxes                                                                         
                                                                                
                                                                                
  Segment revenues by                                                           
  major products and                                                            
  activities            Three months ended                                      
  (Unaudited)                September 30,                          Percentage  
  United States                       2026                          Change      
  segment              (U.S.$ in millions)           2025           2026-2025   
 ────────────────────────────────────────────────────────────────────────────── 
  Generic products                                                              
  (including                             $    718       $  1,175    (39)%       
  biosimilars)                                                                  
  AJOVY                                       138             73    88 %        
  AUSTEDO                                     727            601    21 %        
  BENDEKA and TREANDA                          30             35    (15)%       
  COPAXONE                                     58             62    (8)%        
  UZEDY                                        85             43    96 %        
  Other                                       114            101    13 %        
  Total                                     1,870          2,090    (11)%       
                        Three months ended                          Percentage  
                             September 30,                          Change      
                                      2026           2025           2026-2025   
                        -U.S.$ in millions                                      
  Europe segment                                                                
  Generic products                                                              
  (including OTC and                     $  1,033       $    982    5 %         
  biosimilars)                                                                  
  AJOVY                                        84             66    28 %        
  COPAXONE                                     38             44    (12)%       
  Respiratory                                  54             52    3 %         
  products                                                                      
  Other*                                      111             91    21 %        
  Total                                     1,319          1,235    7 %         
  *Other revenues in                                                            
  the third quarter                                                             
  of 2026 and 2025                                                              
  include the sale                                                              
  of certain product                                                            
  rights                                                                        
                        Three months ended                          Percentage  
                             September 30,                          Change      
                                      2026           2025           2026-2025   
                        -U.S.$ in millions                                      
  International                                                                 
  Markets segment                                                               
  Generic products                                                              
  (including OTC and                     $    407       $    421    (3)%        
  biosimilars)                                                                  
  AJOVY                                        48             30    61 %        
  AUSTEDO                                      24             17    42 %        
  COPAXONE                                      8              8    8 %         
  Other*                                      105             82    28 %        
  Total                                       592            557    6 %         
  *Other revenues in                                                            
  the third quarter                                                             
  of 2026 and 2025                                                              
  include the sale                                                              
  of certain product                                                            
  rights                                                                        
                                                                                
                                                                                
  Segment                                                                       
  revenues by                                                                   
  major products   Nine months ended                                            
  and activities       September 30,                                            
  (Unaudited)                   2026                          Percentage        
  United States            (U.S.$ in                          Change            
  segment                  millions)           2025           2025-2026         
 ────────────────────────────────────────────────────────────────────────────── 
  Generic                          $  1,990       $  2,984    (33)%             
  products                                                                      
  AJOVY                                 341            190    80 %              
  AUSTEDO                             1,963          1,492    32 %              
  BENDEKA /                              85            111    (24)%             
  TREANDA                                                                       
  COPAXONE                              182            179    2 %               
  UZEDY                                 225            136    65 %              
  Other                                 321            321    §                 
  Total                               5,106          5,413    (6)%              
  § Represents an                                                               
  amount less                                                                   
  than 0.5%.                                                                    
                   Nine months ended                                            
                       September 30,                          Percentage        
                                                              Change            
                                2026           2025           2025-2026         
                           -U.S.$ in                                            
                            millions                                            
  Europe segment                                                                
  Generic                          $  3,146       $  3,011    4 %               
  products                                                                      
  AJOVY                                 238            195    22 %              
  COPAXONE                              127            135    (6)%              
  Respiratory                           171            162    6 %               
  products                                                                      
  Other*                                241            223    8 %               
  Total                               3,922          3,726    5 %               
  *Other revenues                                                               
  in the first                                                                  
  nine months of                                                                
  2026 and 2025                                                                 
  include the                                                                   
  sale of certain                                                               
  product rights.                                                               
                   Nine months ended                                            
                       September 30,                          Percentage        
                                                              Change            
                                2026           2025           2025-2026         
                           -U.S.$ in                                            
                            millions                                            
  International                                                                 
  Markets segment                                                               
  Generic                          $  1,212       $  1,298    (7)%              
  products                                                                      
  AJOVY                                 130             78    68 %              
  AUSTEDO                                63             34    82 %              
  COPAXONE                               22             25    (13)%             
  Other*                                239            199    20 %              
  Total                               1,666          1,634    2 %               
  *Other revenues                                                               
  in the first                                                                  
  nine months of                                                                
  2026 and 2025                                                                 
  include the                                                                   
  sale of certain                                                               
  product rights.                                                               
                                                                                
                                                                                
  Free cash flow                                                                
  reconciliation                                                                
  (Unaudited)                                                                   
                                                 Three months ended             
                                                          September             
                                                                30,             
                                                               2026       2025  
                         -U.S. $ in millions                                    
  Net cash provided by                                                          
  (used in) operating                                           241        369  
  activities                                                                    
  Beneficial interest                                                           
  collected in                                                                  
  exchange for                                                  327        274  
  securitized account                                                           
  receivables                                                                   
  Capital investment                                           -120       -136  
  Proceeds from sale of                                                         
  businesses and                                                 47          8  
  long-lived assets,                                                            
  net                                                                           
  Free cash flow         $                                      495    $   515  
                                                                                
                                                                                
  Free cash flow                                                                
  reconciliation                                                                
  (Unaudited)                                                                   
                                       Nine months ended                        
                                               September                        
                                                     30,                        
                                                    2026           2025         
                                     -U.S. $ in millions                        
  Net cash provided by (used                                                    
  in) operating                                             612            491  
  activities                                                                    
  Beneficial interest                                                           
  collected in                                                                  
  exchange for securitized                                  992            932  
  trade                                                                         
  receivables                                                                   
  Capital investment                                       -393           -359  
  Proceeds from sale of                                                         
  businesses and                                             93             34  
  long-lived assets, net                                                        
  Free cash flow                                       $  1,305       $  1,098  
                                                                                
                                                         
  Net debt reconciliation                                
  unaudited                                              
                                          September 30,  
                                    2026                 
  Short-term debt                                 4,038  
  Senior notes and loans                         12,680  
  Total debt                                     16,718  
  Net of cash and cash equivalents                4,085  
  Net debt                             $         12,633  
                                                         
Teva Media Inquiries: [email protected]

Teva Investor Relations Inquiries: [email protected]

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TEVA/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.